Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2015	Mar. 04, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	BIOTIME INC
Entity Central Index Key	0000876343
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 165,569,534
Entity Common Stock, Shares Outstanding		94,894,140
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 42,229	$ 29,487
Available for sale securities	753	3
Trade accounts and grants receivable, net	1,078	1,042
Inventory	1	266
Landlord receivable	567	378
Prepaid expenses and other current assets	2,609	1,229
Total current assets	47,237	32,405
Equipment, net and construction in progress	7,539	2,858
Deferred license fees	322	337
Deposits and other long-term assets	1,299	453
Equity method investment	4,671	0
Intangible assets, net	33,592	38,848
TOTAL ASSETS	94,660	74,901
CURRENT LIABILITIES
Accounts payable and accrued liabilities	9,377	6,803
Capital lease liability, current portion	38	58
Promissory notes, current portion	95	0
Deferred grant income	2,513	0
Deferred license and subscription revenue, current portion	439	208
Total current liabilities	12,462	7,069
LONG-TERM LIABILITIES
Deferred tax liabilities, net	0	4,515
Deferred revenues, net of current portion	615	0
Deferred rent liabilities, net of current portion	158	97
Lease liability	4,400	378
Capital lease liability, net of current portion	26	31
Related party convertible debt, net of discount	324	60
Promissory notes, net of current portion	220	0
Other long term liabilities	8	28
Total long-term liabilities	$ 5,751	$ 5,109
Commitments and contingencies (Note 8)
SHAREHOLDERS' EQUITY
Series A convertible preferred stock, no par value, authorized 2,000 shares as of December 31, 2015 and 2014; none and 70 issued and outstanding as of December 31, 2015 and 2014, respectively	$ 0	$ 3,500
Common stock, no par value, authorized 125,000 shares; issued and outstanding shares; 94,894 issued and 90,421 outstanding as of December 31, 2015 and 83,122 issued and 78,228 outstanding as of December 31, 2014	274,342	234,850
Accumulated other comprehensive (loss)/income	(237)	186
Accumulated deficit	(229,181)	(182,190)
Treasury stock at cost: 4,473 and 4,894 shares at December 31, 2015 and 2014, respectively	(18,033)	(19,890)
BioTime, Inc. shareholders' equity	26,891	36,456
Non-controlling interest	49,556	26,267
Total shareholders' equity	76,447	62,723
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 94,660	$ 74,901

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
SHAREHOLDERS' EQUITY
Series A convertible preferred stock, par value (in dollars per share)	$ 0	$ 0
Series A convertible preferred stock, authorized (in shares)	2,000,000	2,000,000
Series A convertible preferred stock, issued (in shares)	0	70,000
Series A convertible preferred stock outstanding (in shares)	0	70,000
Common shares, par value (in dollars per share)	$ 0	$ 0
Common shares, authorized (in shares)	125,000,000	125,000,000
Common shares, issued (in shares)	94,894,140	83,121,698
Common shares, outstanding (in shares)	90,421,554	78,227,756
Treasury stock (in shares)	4,472,586	4,893,942

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
REVENUES:
Subscription and advertisement revenues	$ 1,357	$ 1,173	$ 2,218
Royalties from product sales	719	398	367
Grant income	4,502	3,297	1,573
Sale of research products and services	458	376	276
Total revenues	7,036	5,244	4,434
Cost of sales	(1,107)	(837)	(793)
Gross Profit	5,929	4,407	3,641
OPERATING EXPENSES:
Research and development	(42,604)	(37,533)	(26,609)
Acquired in-process research and development	0	0	(17,459)
General and administrative	(29,134)	(17,556)	(15,559)
Total operating expenses	(71,738)	(55,089)	(59,627)
Loss from operations	(65,809)	(50,682)	(55,986)
OTHER INCOME/(EXPENSES):
Interest income/(expense), net	(640)	(89)	0
BioTime's share of losses in equity method investment in Ascendance	(35)	0	0
Gain on investment (Note 12)	3,694	0	0
Other income/(expense), net	(160)	(384)	(204)
Total other income/(expense), net	3,159	(473)	(204)
LOSS BEFORE INCOME TAX BENEFIT	(62,650)	(51,154)	(56,191)
Deferred income tax benefit	4,516	7,376	3,281
NET LOSS	(58,134)	(43,779)	(52,910)
Net loss attributable to non-controlling interest	11,143	7,367	9,026
NET LOSS ATTRIBUTABLE TO BIOTIME, INC.	(46,991)	(36,412)	(43,883)
Dividends on preferred stock	(415)	(87)	0
NET LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (47,406)	$ (36,499)	$ (43,883)
BASIC AND DILUTED NET LOSS PER COMMON SHARE (in dollars per share)	$ (0.59)	$ (0.55)	$ (0.81)
WEIGHTED AVERAGE NUMBER OF COMMON STOCK OUTSTANDING: BASIC AND DILUTED (in shares)	79,711	66,467	54,226

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
NET LOSS	$ (58,134,000)	$ (43,779,000)	$ (52,910,000)
Other comprehensive income/(loss), net of tax:
Change in foreign currency translation	(424,000)	125,000	119,000
Change in unrealized (loss) on available for sale securities, net of taxes	1,000	0	0
Unrealized loss on available-for-sale securities, net of taxes	0	(2,000)	3,000
COMPREHENSIVE LOSS	(58,557,000)	(43,655,000)	(52,788,000)
Less: Comprehensive loss attributable to noncontrolling interest	(11,143,000)	(7,367,000)	(9,026,000)
COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS BEFORE PREFERRED STOCK DIVIDEND	(47,414,000)	(36,288,000)	(43,762,000)
Preferred stock dividend	(415,000)	(87,000)	0
COMPREHENSIVE LOSS ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (47,829,000)	$ (36,375,000)	$ (43,762,000)

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)	Preferred Shares [Member]	Common Shares [Member]	Treasury Shares [Member]	Contributed Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Total
BALANCE at Dec. 31, 2012	$ 0	$ 119,821,000	$ (8,375,000)	$ 94,000	$ (101,896,000)	$ 14,710,000	$ (60,000)	$ 24,294,000
BALANCE (in shares) at Dec. 31, 2012	0	51,183,000	(1,800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common shares issued as part of investment in subsidiary		$ 38,485,000	$ (38,485,000)					0
Common shares issued as part of investment in subsidiary (in shares)		9,809,000	(9,809,000)
8,000,000 Warrants issued as part of investment in subsidiary		$ 18,276,000						18,276,000
Sale of common shares, net of fees paid and amortized and syndication costs		$ 22,297,000						22,297,000
Sale of common shares, net of fees paid and amortized and syndication costs (in shares)		6,284,000
Warrants issued to outside investors		$ 1,849,000						1,849,000
Common shares issued for rent		$ 254,000						254,000
Common shares issued for rent (in shares)		74,000
Common shares issued for consulting services		$ 173,000						173,000
Common shares issued for consulting services (in shares)		42,000
Exercise of options		$ 46,000						46,000
Exercise of options (in shares)		20,000
Shares retired as payment for exercise of options								0
Stock options granted for compensation		$ 2,144,000						2,144,000
Stock options granted for compensation in subsidiaries		111,000				790,000		901,000
Sale of treasury stock			$ 3,826,000					3,826,000
Sale of treasury stock (in shares)			911,000
Dividends on preferred stock								0
Outside investment in OncoCyte and Cell Cure Neurosciences						5,256,000		5,256,000
Outside investment in subsidiary with assets						15,733,000		15,733,000
Foreign currency translation gain (loss)							119,000	119,000
Unrealized (loss) gain on available-for-sale securities							3,000	3,000
NET LOSS					(43,882,000)	(9,028,000)		(52,910,000)
BALANCE at Dec. 31, 2013	$ 0	$ 203,456,000	$ (43,034,000)	94,000	(145,778,000)	27,461,000	62,000	42,262,000
BALANCE (in shares) at Dec. 31, 2013	0	67,412,000	(10,698,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common shares, net of fees paid and amortized and syndication costs		$ 43,827,000						43,827,000
Sale of common shares, net of fees paid and amortized and syndication costs (in shares)		14,173,000
Common shares issued for rent								0
Common shares issued for consulting services								0
Exercise of options		$ 1,192,000						1,192,000
Exercise of options (in shares)		2,060,000
Shares retired as payment for exercise of options		$ (973,000)						(973,000)
Shares retired as part of exercise of options (in shares)		(367,000)
Shares retired to pay for employee's taxes		$ (415,000)						(415,000)
Shares retired to pay for employee's taxes (in shares)		(156,000)
Tax liability on treasury shares sold by Asterias		$ (3,611,000)						(3,611,000)
Stock options granted for compensation		2,409,000						2,409,000
Stock options granted for compensation in subsidiaries						1,808,000		1,808,000
Restricted stock granted for compensation						234,000		234,000
Susidiary warrants issued to outside investors as part of sale of treasury stock						3,184,000		3,184,000
Sale of treasury stock		(11,042,000)	$ 23,144,000					12,102,000
Sale of treasury stock (in shares)			5,804,000
Sale of preferred stock	$ 3,500,000							3,500,000
Sale of preferred stock (in shares)	70,000
Dividends on preferred stock				(87,000)				(87,000)
Exercise of subsidiary options						8,000		8,000
Outside investment in OncoCyte and Cell Cure Neurosciences						939,000		939,000
Foreign currency translation gain (loss)							125,000	125,000
Unrealized (loss) gain on available-for-sale securities							(2,000)	(2,000)
NET LOSS					(36,412,000)	(7,367,000)		(43,779,000)
BALANCE at Dec. 31, 2014	$ 3,500,000	$ 234,843,000	$ (19,890,000)	7,000	(182,190,000)	26,267,000	186,000	$ 62,723,000
BALANCE (in shares) at Dec. 31, 2014	70,000	83,122,000	(4,894,000)					78,227,756
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common shares, net of fees paid and amortized and syndication costs		$ 33,897,000						$ 33,897,000
Sale of common shares, net of fees paid and amortized and syndication costs (in shares)		10,738,000
Common shares issued for rent								0
Common shares issued for consulting services								0
Exercise of options		$ 621,000						621,000
Exercise of options (in shares)		155,000
Shares retired as payment for exercise of options								0
Warrants exercised		$ 19,000						19,000
Warrants exercised (in shares)		4,000
Contingently issuable subsidiary warrants						65,000		65,000
Stock options granted for compensation		$ 2,003,000						2,003,000
Stock options granted for compensation in subsidiaries						8,223,000		8,223,000
Restricted stock granted for compensation						822,000		822,000
Dividend in kind					(712,000)	712,000
Subsidiary shares retired to pay for employee's taxes						(98,000)		(98,000)
Subsidiary warrants exercised						11,700,000		11,700,000
Sale of treasury stock		(496,000)	$ 1,857,000					1,361,000
Sale of treasury stock (in shares)			421,000
Conversion of preferred stock to common stock	$ (3,500,000)	$ 3,500,000						0
Conversion of preferred stock to common stock (in shares)	(70,000)	875,000
Dividends on preferred stock		$ (45,000)		(7,000)				(415,000)
Exercise of subsidiary options						33,000		33,000
Subsidiary shares issued in lieu of cash for services received						486,000		486,000
Outside investment in OncoCyte and Cell Cure Neurosciences						3,555,000		3,555,000
Sale of subsidiary shares at- the- market, net of fees paid and amortized						9,646,000		9,646,000
Foreign currency translation gain (loss)							(424,000)	(424,000)
Unrealized (loss) gain on available-for-sale securities							1,000	1,000
NET LOSS					(45,916,000)	(11,855,000)		(58,134,000)
BALANCE at Dec. 31, 2015	$ 0	$ 274,342,000	$ (18,033,000)	$ 0	$ (229,181,000)	$ 49,556,000	$ (237,000)	$ 76,447,000
BALANCE (in shares) at Dec. 31, 2015	0	94,894,000	(4,473,000)					90,421,554

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (46,991)	$ (36,412)	$ (43,883)
Net loss allocable to non-controlling interest	(11,143)	(7,367)	(9,026)
Gain on sale of assets	(3,694)	0	0
BioTime's share of losses of equity method investment	35	0	0
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Acquired in-process research and development	0	0	17,459
Depreciation expense	1,078	1,051	657
Amortization of intangible assets	5,256	7,360	3,296
Amortization of deferred consulting fees	0	19	65
Amortization of deferred license fees	114	110	109
Amortization of deferred license, royalty and subscription revenues	102	(1)	(915)
Amortization of prepaid rent in common stock	63	85	85
Stock-based compensation	11,050	4,455	3,218
Subsidiary common stock issued in lieu of cash for services	486	0	0
Amortization of discount on related party convertible debt	245	56	0
Loss/(gain) on sale or write-off of equipment	1	9	(5)
Write-off for uncollectible receivables	0	(16)	0
Contingently issuable subsidiary warrants in lieu of investor relations expenses	65	0	0
Deferred income tax benefit	(4,516)	(7,376)	(3,281)
Changes in operating assets and liabilities:
Accounts receivable, net	(248)	(74)	(181)
Grant receivable	168	11	560
Inventory	(75)	(87)	(123)
Prepaid expenses and other current assets	(1,458)	(86)	428
Other long-term assets	(100)	0	(15)
Accounts payable and accrued liabilities	1,673	(470)	2,142
Accrued interest on related party convertible debt	19	4	0
Other long-term liabilities	(20)	(160)	(58)
Deferred grant income	2,513	0	0
Deferred rent liabilities	61	61	(22)
Deferred revenues	772	(26)	(19)
Net cash used in operating activities	(44,544)	(38,854)	(29,509)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(1,241)	(483)	(2,277)
Payments on construction in progress	(4,093)	(219)	0
Purchase of foreign available-for-sale securities	(748)	0	0
Payment for Ascendance equity method investment	(500)	0	0
Payment of transaction fees to Geron	0	0	(978)
Payment of syndication fees incurred	0	0	(376)
Proceeds from the sale of equipment	0	9	31
Security deposit paid, net	(859)	(315)	(65)
Cash used in investing activities	(7,441)	(1,008)	(3,665)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	621	219	46
Proceeds from sale of preferred stock	0	3,500	0
Proceeds from issuance of common shares	34,123	44,150	25,939
Fees paid on sale of common shares	0	(323)	(818)
Proceeds from exercises of warrants	20	0	0
Proceeds from exercise of subsidiary stock options	33	8	0
Proceeds from sale of treasury shares	1,347	0	0
Proceeds from exercise of subsidiary warrants	11,700	0	0
Proceeds from sale of treasury shares and issuance of subsidiary warrants	0	15,156	3,842
Proceeds from sale of subsidiary common shares	13,639	468	5,255
Fees paid on sale of subsidiary common shares	(693)	0	0
Reimbursement from landlord on construction in progress	3,789	0	0
Proceeds from issuance of related party convertible debt	255	471	0
Repayment of capital lease obligation	(59)	(26)	0
Net cash provided by financing activities	64,775	63,623	34,264
Effect of exchange rate changes on cash and cash equivalents	(48)	230	56
NET INCREASE IN CASH AND CASH EQUIVALENTS	12,742	23,991	1,146
CASH AND CASH EQUIVALENTS:
At beginning of year	29,487	5,496	4,350
At end of year	42,229	29,487	5,496
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during year for interest	119	91	3
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES :
Common shares issued to Cell Cure in exchange for Cell Cure shares	0	0	3,500
Common shares issued for consulting services	0	0	173
Common shares issued for rent	0	0	254
Intangible assets acquired from Geron	0	0	29,017
Common shares issued to Asterias upon consummation of Asset Contribution Agreement (Treasury shares)	0	0	34,985
Employee options exercised with common stock	0	973	0
Capital expenditure funded by capital lease borrowing	34	115	0
Construction in progress in accounts payable and accrued expenses	524	186	0
Landlord receivable	(567)	(378)	0
Lease liability	4,400	378	0
Warrants issued to Asterias upon consummation of Asset Contribution Agreement	0	0	18,276
Equity method investment in Ascendance in exchange for assets	$ 4,706	$ 0	$ 0

Organization, Basis of Presentation and Liquidity

12 Months Ended

Dec. 31, 2015

Organization, Basis of Presentation and Liquidity [Abstract]

Organization, Basis of Presentation and Liquidity

1. Organization, Basis of Presentation and Liquidity

General – BioTime is a biotechnology company focused on the field of regenerative medicine; specifically pluripotent stem cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. Pluripotent stem cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime and its subsidiaries and nonconsolidated investee are developing stem cell products for research and therapeutic use. BioTime’s primary therapeutic products are based on its HyStem^® hydrogel technology and include Renevia^® a product currently in clinical trials in Europe to facilitate cell transplantation. Asterias Biotherapeutics, Inc. (“Asterias,” NYSE MKT: AST) is developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 neural cells in spinal cord injury, and AST-VAC1 and AST-VAC2, pluripotent stem cell-derived cancer vaccines. OncoCyte Corporation (“OncoCyte” NYSE MKT: OCX) is developing laboratory diagnostic tests for certain types of cancer. ES Cell International Pte Ltd. (“ESI”), a Singapore private limited company, is providing its National Institutes of Health (“NIH”) approved hES cell lines, manufactured under current good manufacturing practices (“cGMP”), to researchers focused on pre-clinical applications. OrthoCyte Corporation (“OrthoCyte”) is developing bone grafting products to treat orthopedic disorders, diseases and injuries. ReCyte Therapeutics, Inc. (“ReCyte Therapeutics”) is developing therapies to treat a variety of cardiovascular and related ischemic disorders, as well as related products for research. Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological disorders, including the development of retinal pigment epithelial cells for the treatment of the dry form of age related macular degeneration. LifeMap Sciences, Inc. (“LifeMap Sciences”) sell subscriptions to use GeneCards^®, the leading human gene database, and other data base and genetic research software products. LifeMap Sciences’ subsidiary LifeMap Solutions, Inc. (“LifeMap Solutions”) is developing mobile health software products in partnership with the Icahn Institute for Genomics and Multiscale Biology. Ascendance Biotechnology, Inc. (“Ascendance”), recently organized company in which BioTime has an investment accounted for under the equity method (see Notes 2 and 12), develops and markets liver cell based micro assays for toxicity of drugs under development, and also is developing and marketing products for stem cell research.

BioTime has also developed Hextend^®, a blood plasma volume expander marketed by licensees in the United States and South Korea for use in surgery, emergency trauma treatment and other applications. BioTime’s operating revenues are now derived primarily from research grants, from royalties and licensing fees, and advertising from the marketing of the LifeMap Sciences database products, and from the sale of products for research.

Use of estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions used include determining valuation allowances for uncollectible accounts receivables, deferred income taxes, and tax reserves, including valuation allowances for deferred tax assets, obsolete and excess inventory, evaluation of asset impairment, in determining the useful life of depreciable and definite-lived intangible assets, useful life of licensed technologies or licensed research products, valuing investments in nonconsolidated investees using the equity method, and in the variables and assumptions used to calculate and record stock-based compensation. Actual results could differ materially from those estimates.

Principles of consolidation – BioTime’s consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2015.

Subsidiary	Field of Business	BioTime Ownership	Country
Asterias Biotherapeutics, Inc.	Human therapeutic products from stem cells, focused initially in the fields of neurology and oncology	57.1%	USA
Cell Cure Neurosciences Ltd.	Products to treat age-related macular degeneration	62.5%⁽¹⁾	Israel
ES Cell International Pte Ltd	Stem cell products for research, including clinical grade cell lines produced under cGMP	100%	Singapore
LifeMap Sciences, Inc.	Biomedical, gene, disease, and stem cell databases and tools	77.9%	USA
LifeMap Sciences, Ltd.	Biomedical, gene, disease, and stem cell databases and tools	(2)	Israel
LifeMap Solutions, Inc.	Mobile health software	(2)	USA
OncoCyte Corporation	Cancer diagnostics	57.7%	USA
OrthoCyte Corporation	Developing bone grafting products for orthopedic diseases and injuries	100%	USA
ReCyte Therapeutics, Inc.	Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity	94.8%	USA

(1)

Includes shares owned by BioTime, Asterias and ESI.

(2)

LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.

All material intercompany accounts and transactions have been eliminated in consolidation. As of December 31, 2015, BioTime consolidated Asterias, ReCyte Therapeutics, OncoCyte, OrthoCyte, ESI, Cell Cure Neurosciences, BioTime Asia, Limited (“BioTime Asia”), LifeMap Sciences, LifeMap Sciences, Ltd., and LifeMap Solutions as BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the non-controlling interest is reflected as a separate element of shareholders’ equity on BioTime’s consolidated balance sheets.

Liquidity – Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, payments from research grants, royalties from product sales and sales of research products and services. At December 31, 2015, BioTime had an accumulated deficit of $229.2 million, working capital of $34.8 million and shareholders’ equity of $76.4 million. BioTime has evaluated its projected cash flows for it and its subsidiaries and believes that its cash, cash equivalents and available for sale securities of $43.0 million as of December 31, 2015. BioTime will be sufficient to fund its operations at least through December 31, 2016. However, clinical trials being conducted by BioTime’s subsidiaries, Asterias and Cell Cure Neurosciences will be funded in part with funds from grants and not from cash on hand. If either Asterias or Cell Cure Neurosciences were to lose its grant funding it may be required to delay, postpone, or cancel its clinical trials or limit the number of clinical trial sites, or otherwise reduce or curtail its operations unless it is able to obtain adequate financing from another source that could be used for its clinical trial. Also, OncoCyte will need to raise additional capital during 2016 if, based on the results of its research and development efforts, it determines to establish a CLIA certified laboratory and commence marketing its first cancer diagnostic test.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Revenue recognition – BioTime complies with ASC 605-10 and recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Grant income and the sale of research products and services are recognized as revenue when earned. Revenues from the sale of research products and services are primarily derived from the sale of hydrogels and stem cell products. Royalty revenues consist of product royalty payments. License fee revenues consist primarily of subscription and advertising revenue from LifeMap Sciences’ online databases and are recognized based upon respective subscription or advertising periods. Other license fees under certain license agreements were recognized during prior periods when earned and reasonably estimable. Royalties earned on product sales are recognized as revenue in the quarter in which the royalty reports are received from the licensee, rather than the quarter in which the sales took place. When BioTime or a subsidiary is entitled to receive up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime or its subsidiary has no continuing performance obligations, the fees are recognized as revenues when collection is reasonably assured. When BioTime or a subsidiary receives up-front nonrefundable licensing or similar fees pursuant to agreements under which BioTime or its subsidiary does have continuing performance obligations, the fees are deferred and amortized ratably over the performance period. If the performance period cannot be reasonably estimated, BioTime amortizes nonrefundable fees over the life of the contract until such time that the performance period can be more reasonably estimated. Milestone payments, if any, related to scientific or technical achievements are recognized in income when the milestone is accomplished if (a) substantive effort was required to achieve the milestone, (b) the amount of the milestone payment appears reasonably commensurate with the effort expended, and (c) collection of the payment is reasonably assured.

Cash and cash equivalents – BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Trade accounts and grants receivable, net – Net trade receivables amounted to $754,000 and $549,000 and grants receivable amounted to $324,000 and $493,000 as of December 31, 2015 and December 31, 2014, respectively. Net trade receivables include allowance for doubtful accounts of approximately $101,000 as of December 31, 2015 for those amounts deemed uncollectible by BioTime. BioTime evaluates the collectability of its receivables based on a variety of factors, including the length of time receivables are past due and significant one-time events and historical experience. An additional reserve for individual accounts will be recorded if BioTime becomes aware of a customer’s inability to meet its financial obligations, such as in the case of bankruptcy filings or deterioration in the customer’s operating results or financial position. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted.

Concentrations of credit risk – Financial instruments that potentially subject BioTime to significant concentrations of credit risk consist primarily of cash and cash equivalents. BioTime limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, BioTime has not experienced any losses on such accounts.

Fair Value Measurements – Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50):

●

Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

●

Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

●

Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

Available for sale securities in foreign investments

BioTime accounts for the shares it holds through its consolidated subsidiary LifeMap Sciences Ltd as available-for-sale foreign equity securities in accordance with ASC 320-10-25, Investments – Debt and Equity Securities, as the shares have a readily determinable fair value quoted on the Tel Aviv Stock Exchange, or TASE, under the trading symbol (TASE: HDST) and held principally for sale to meet future working capital needs and are denominated in Israeli New Shekels (ILS). These securities are measured at fair value and reported as current assets on the balance sheet based on the closing trading price of the security as of the date being presented. Unrealized holding gains and losses, net of tax, are reported in other comprehensive income (loss). Realized gains and losses, and declines in value judged to be other-than-temporary related to equity securities, are included in other income or expenses, net, in the consolidated statements of operations.

On December 21, 2015, LifeMap Sciences acquired 9,180,000 shares of HDST common stock for a cost of approximately $850,000 and, as of December 31, 2015, the HDST common stock is shown as available for sale securities valued at $753,000. During the year ended December 31, 2015, LifeMap Sciences recorded an approximate unrealized loss of $100,000 on the HDST securities included in other comprehensive loss.

Fair value of financial instruments – The fair value of BioTime’s assets and liabilities, which qualify as financial instruments under FASB guidance regarding disclosures about fair value of financial instruments, approximate the carrying amounts presented in the accompanying consolidated balance sheets. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

Inventory – Inventories are stated at the lower of cost or market. Cost, which includes amounts related to materials, labor, and overhead, is determined in a manner which approximates the first-in, first-out (“FIFO”) method.

Investments in Common Stock of Privately Held Companies – BioTime evaluates investments held in common stock to determine if the investee is a variable interest entity (“VIE”) and, if so, whether BioTime is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required in accordance with accounting guidance for consolidations under Accounting Standards Codification (“ASC”) 810-10. If the investee is determined not to be a VIE, then the investee is evaluated under the Voting Interest model, to determine whether BioTime has a controlling financial interest and consolidation of the entity is required. If consolidation of the entity is not required under either the VIE assessment or the Voting Interest model, the investment is evaluated to determine if the equity method of accounting should be applied in accordance with ASC 323, Investments – Equity Method and Joint Ventures. The equity method applies to investments in common stock or in‑substance common stock where BioTime exercises significant influence over, but does not control, the investee, typically represented by ownership of 20% or more of the voting interests of an entity.

BioTime initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on BioTime’s share of earnings or losses from the investment included in other income or expenses, net, on the consolidated statements of operations. The equity method investment balance is shown in noncurrent assets of the consolidated balance sheets.

BioTime reviews investments accounted for under the equity method for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be fully recoverable. If a determination is made that an other-than-temporary impairment exists, BioTime writes down its investment to fair value.

Equipment, net and construction in progress – Equipment and construction in progress is stated at cost. Equipment is being depreciated using the straight-line method over their estimated useful lives ranging from 36 to 120 months. Construction in progress is not depreciated until the underlying asset is placed into service (see Note 4).

Intangible assets, net – Intangible assets with finite useful lives are amortized over their estimated useful lives and intangible assets with indefinite lives are not amortized but rather are tested at least annually for impairment. Acquired in-process research and development intangible assets are accounted for depending on whether they were acquired as part of an acquisition of a business, or as assets that do not constitute a business. When acquired in conjunction with the acquisition of a business, these assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts and are capitalized as an asset. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. However, when acquired in conjunction with an acquisition of assets that do not constitute a business (such as the acquisition of assets by Asterias from Geron Corporation), in accordance with ASC 805-50, such intangible assets related to in-process research and development (“IPR&D”) are expensed upon acquisition.

Treasury stock – BioTime accounts for BioTime common shares issued to subsidiaries for future potential working capital needs as treasury stock on the consolidated balance sheet. BioTime has registered the BioTime common shares held by its subsidiaries for sale under the Securities Act of 1933, as amended (the “Securities Act”) to enhance the marketability of the shares.

Warrants to purchase common stock – BioTime generally accounts for warrants issued in connection with equity financings as a component of equity. None of the warrants issued by BioTime as of December, 2015 include a conditional obligation to issue a variable number of shares; nor was there a deemed possibility that BioTime may need to settle the warrants in cash.

Cost of sales – BioTime accounts for the cost of research products acquired for sale and any royalties paid as a result of any revenues in accordance with the terms of the respective licensing agreements as cost of sales on the consolidated statement of operations.

Patent costs – Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.

Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation.

Research and development – Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses including salaries, payroll taxes, consulting fees, research and laboratory fees, rent of research facilities, amortization of intangible assets, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. BioTime expenses research and development costs as such costs are incurred. Research and development expenses incurred and reimbursed under grants approximate the grant income recognized in the consolidated statements of operations.

General and administrative – General and administrative expenses consist principally of compensation and related benefits, including stock-based compensation, for executive and corporate personnel; professional and consulting fees; and allocated overhead.

Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses –In countries in which BioTime operates, where the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Revenues and expenses and cash flows are translated using an approximate weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income or loss on the consolidated balance sheet. For the fiscal years ended December 31, 2015 and 2014, comprehensive loss includes loss of $423,000 and gain of $122,900, respectively which is largely from foreign currency translation. For the fiscal year ended December 31, 2015 foreign currency translation loss amounted to $424,000. For the fiscal year ended December 31, 2014, foreign currency translation gain amounted to $125,000.

For transactions denominated in other than the functional currency of BioTime, transactional gains and losses are recorded in other income and expense included in the consolidated statements of operations. Foreign currency transaction gain amounted to $5,000 for the year ended December 31, 2015, and a $338,000 loss for the year ended December 31, 2014.

Income taxes – BioTime accounts for income taxes in accordance with ASC 740, Income Taxes, which prescribe the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. ASC 740 guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. Beginning October 1, 2013, Asterias began filing separate U.S. federal income tax returns but effectively BioTime combined Asterias’ tax provision with BioTime’s consolidated financial statements. For California, Asterias’ activities will continue to be included in BioTime’s combined tax return. BioTime recognizes accrued interest and penalties related to unrecognized tax benefits, if any, as income tax expense, however, no amounts were accrued for the payment of interest and penalties as of December 31, 2015 and 2014. BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2011. Although the statute is closed for purposes of assessing additional income and tax in those years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore the statute should be considered open as it relates to the net operating loss and credit carryforwards. Any potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, state and local and foreign tax laws. Management does not expect that the total amount of unrecognized tax benefits will materially change over the next year.

Stock-based compensation – BioTime follows accounting standards governing share-based payments, which require the measurement and recognition of compensation expense for all share-based payment awards made to directors and employees, including employee stock options, based on estimated fair values less estimated forfeitures. Consistent with FASB guidelines, BioTime utilizes the Black-Scholes Merton option pricing model for valuing share-based payment awards. BioTime’s determination of fair value of share-based payment awards on the date of grant using that option-pricing model is affected by BioTime’s stock price as well as by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, BioTime’s expected stock price volatility over the term of the awards; the expected term of options granted, derived from historical data on employee exercises and post-vesting employment termination behavior; and a risk-free interest rate based on the U.S. Treasury rates in effect during the corresponding period of grant. Although the fair value of employee stock options is determined in accordance with FASB guidance, changes in the subjective assumptions can materially affect the estimated value.

Impairment of long-lived assets – BioTime’s long-lived assets, including intangible assets, are reviewed annually for impairment and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. If an impairment indicator is present, BioTime will evaluate recoverability by a comparison of the carrying amount of the assets to future undiscounted net cash flows expected to be generated by the assets. If the assets are impaired, the impairment recognized is measured by the amount by which the carrying amount exceeds the estimated fair value of the assets.

Deferred license fees – Deferred license fees consist of fees paid to acquire rights to use the proprietary technologies of third parties which are being amortized over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life of any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life of a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime periodically reviews the continued appropriateness of the 10 year estimated useful life for impairments that might occur earlier than the original expected useful lives.

Loss per share – BioTime applies the two-class method for calculating basic earnings per share. Under the two-class method, net income, if any, will be reduced by preferred stock dividends and the residual amount is allocated between common stock and other participating securities based on their participation rights. Participating securities are comprised of Series A convertible preferred stock and participate in dividends, whether declared or not. Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock subject to repurchase by BioTime, if any, during the period. For periods in which BioTime reported a net loss, the participating securities are not contractually obligated to share in the losses of BioTime, and accordingly, no losses have been allocated to the participating securities. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common stock, which are comprised of stock options and warrants, using the treasury-stock method, and Series A convertible preferred stock, using the if-converted method. Because BioTime reported losses attributable to common stockholders for all periods presented, all potentially dilutive common stock are antidilutive for those periods. Diluted net loss per share for years ended December 31, 2015, 2014, and 2013 excludes any effect from 4,472,586 treasury shares, 5,194,313 options and 10,109,860 warrants, 4,893,942 treasury shares, 3,974,326 options and 9,194,679 warrants, and 10,697,715 treasury shares, 4,567,135 options and 9,751,615 warrants, respectively because their inclusion would be antidilutive.

Recently Issued Accounting Pronouncements – The following accounting standards, which are not yet effective, are presently being evaluated by BioTime to determine the impact that they might have on its consolidated financial statements.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)”, which requires lessees recognize assets and liabilities for leases with lease terms greater than twelve months in the statement of financial position. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The update is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that reporting period. Early adoption is permitted. BioTime is currently evaluating the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740)”: Balance Sheet Classification of Deferred Taxes”, which changes how deferred taxes are classified on company’s balance sheets. The ASU eliminates the current requirement to present deferred tax liabilities and assets as current and noncurrent on the balance sheet. Instead, companies will be required to classify all deferred tax assets and liabilities as noncurrent. The amendments are effective for annual financial statements beginning after December 15, 2016, and interim periods within those annual periods. BioTime is currently evaluating the impact the adoption of ASU 2015-17 will have on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”, which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP.

The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). BioTime is currently evaluating the impact of BioTime’s pending adoption of ASU 2014-09 on BioTime’s consolidated financial statements and has not yet determined the method by which it will adopt the standard in fiscal 2018.

In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” that replaces the existing accounting standards for the measurement of inventory. ASU 2015-11 requires a company to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation”. The effective date of ASU 2015-11 is for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. BioTime does not expect the adoption of ASU 2015-11 will have a material effect on its consolidated financial statements.

Inventory, net	12 Months Ended
Inventory, net	Dec. 31, 2015
Inventory, net [Abstract]
Inventory, net	3. Inventory, net BioTime held $1,000 and $266,000 of inventory of raw materials and finished goods products on-site at its corporate headquarters in Alameda, California at December 31, 2015 and 2014, respectively. Finished goods products of $12,800 were held by a third party on consignment at December 31, 2014.

Equipment, net and construction in progress

12 Months Ended

Dec. 31, 2015

Equipment, net and construction in progress [Abstract]

Equipment, net and construction in progress

4. Equipment, net and construction in progress

At December 31, 2015 and 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following (in thousands):

	2015			2014
Equipment, furniture and fixtures	$	10,757		$	4,871
Construction in progress		93			406
Accumulated depreciation		(3,311	)		(2,419	)
Equipment, net and construction in progress	$	7,539		$	2,858

Equipment, furniture and fixtures at December 31, 2015 include $33,800 and $115,000 financed by capital lease borrowings in 2015 and 2014, respectively. Depreciation expense amounted to $1.1 million and $1.1 million for the years ended December 31, 2015 and 2014, respectively.

Construction in progress

Construction in progress of $93,100 as of December 31, 2015 entirely relates to the improvements for BioTime’s new Alameda Facilities (see Note 13).

There were no construction in progress remaining as of December 31, 2015 related to Asterias’ Fremont facility as the asset was placed into use in December. Under the terms of the lease agreement, the landlord provided Asterias with a tenant improvement allowance of $4.4 million, which Asterias used to construct a laboratory and production facility. As of December 31, 2015, Asterias received $3.8 million from the landlord with a remaining $0.6 million receivable.

Reimbursable amounts due to Asterias but not yet paid by the landlord as of year-end are recorded as a landlord receivable with a corresponding increase to lease liability since Asterias has contractually earned the right to receive that payment. The facility was completed and the assets were placed into service in December 2015.

Intangible assets, net

12 Months Ended

Dec. 31, 2015

Intangible assets, net [Abstract]

Intangible assets, net

5. Intangible assets, net

At December 31, 2015 and 2014, intangible assets and accumulated intangible assets were comprised of the following (in thousands):

	2015			2014
Intangible assets	$	52,563		$	52,562
Accumulated amortization		(18,971	)		(13,714	)
Intangible assets, net	$	33,592		$	38,848

BioTime amortizes its intangible assets over an estimated period of 10 years on a straight line basis. BioTime recognized $5.3 million and $ 7.4 million in amortization expense of intangible assets during the years ended December 31, 2015 and 2014, respectively. Asterias recorded an adjustment to reduce the gross cost of the intangible assets by $2.2 million with a corresponding reduction to the accumulated amortization balance of $270,000, resulting in an additional amortization expense of $1.9 million included in the statements of operations for the year ended December 31, 2014.

Amortization of intangible assets for periods subsequent to December 31, 2015 is as follows (in thousands):

Year Ended December 31,	Amortization Expense
2016	$	5,256
2017		5,256
2018		5,256
2019		5,256
2020		4,480
Thereafter		8,088
Total	$	33,592

Royalty Obligation and Deferred License Fees

12 Months Ended

Dec. 31, 2015

Royalty Obligation and Deferred License Fees [Abstract]

Royalty Obligation and Deferred License Fees

6. Royalty Obligation and Deferred License Fees

BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life of any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime periodically reviews its amortization periods for impairments that might occur earlier than the original expected useful lives.

WARF License—Research Products

On January 3, 2008, BioTime entered into a Commercial License and Option Agreement with Wisconsin Alumni Research Foundation (“WARF”). The WARF license permits BioTime to use certain patented and patent pending technology belonging to WARF, as well as certain stem cell materials, for research and development purposes, and for the production and marketing of products used as research tools, including in drug discovery and development. BioTime or ReCyte Therapeutics will pay WARF royalties on the sale of products and services using the technology or stem cells licensed from WARF. The royalty will range from 2% to 4%, depending on the kind of products sold. The royalty rate is subject to certain reductions if BioTime also becomes obligated to pay royalties to a third party in order to sell a product. The $295,000 licensing fees less accumulated amortization of $210,100 and $151,000 were included in deferred license fees in BioTime’s consolidated balance sheet as of December 31, 2015 and 2014, respectively.

ReCyte Therapeutics Licenses from Ocata

On July 10, 2008, ReCyte Therapeutics entered into a License Agreement with Advanced Cell Technology, Inc., now Ocata Therapeutics, Inc. (“Ocata”) under which ReCyte Therapeutics acquired exclusive worldwide rights to use Ocata’s technology for methods to accelerate the isolation of novel cell strains from pluripotent stem cells. ReCyte subsequently assigned the license to BioTime. ReCyte Therapeutics paid Ocata a $250,000 license fee and will pay an 8% royalty on sales of products, services, and processes that utilize the licensed technology. Once a total of $1 million of royalties has been paid, no further royalties will be due. The license will expire in twenty years or upon the expiration of the last to expire of the licensed patents, whichever is later. The $250,000 license fee less accumulated amortization of $209,900 and $184,900 are included in deferred license fees in BioTime’s consolidated balance sheet as of December 31, 2015 and 2014, respectively.

Cell Cure Neurosciences License from Hadasit

Cell Cure Neurosciences has entered into an Amended and Restated Research and License Agreement with Hadasit under which it received an exclusive license to use certain of Hadasit’s patented technologies for the development and commercialization for pluripotent stem cell-derived cell replacement therapies for retinal degenerative diseases. Cell Cure Neurosciences paid Hadasit 249,100 New Israeli Shekels (approximately US$63,900) as a reimbursement for patent expenses incurred by Hadasit, and pays Hadasit quarterly fees for research and product development services under a related Product Development Agreement.

If Cell Cure Neurosciences grants a sublicense to any strategic partner comparable to Teva Pharmaceutical Industries Ltd. (a “Strategic Partner”), Cell Cure Neurosciences will pay Hadasit 30% of all sublicensing payments made by the Strategic Partner to Cell Cure Neurosciences, other than payments for research, reimbursements of patent expenses, loans or equity investments, provided that the minimum payments due to Hadasit in respect of amounts which constitute royalties based on sales of licensed products by the Strategic Partner, its affiliates or sublicensees shall not be less than 1.2% of the underlying net sales.

If Cell Cure Neurosciences does not grant a sublicense to a Strategic Partner but instead commercializes OpRegen^® itself or sublicenses the Hadasit patents to a third party for the completion of development or commercialization of OpRegen^®, Cell Cure Neurosciences will pay Hadasit a 5% royalty on sales of products that utilize the licensed technology. Cell Cure Neurosciences will also pay sublicensing fees ranging from 10% to 30% of any payments Cell Cure Neurosciences receives from sublicensing the Hadasit patents. Commencing in January 2017, Hadasit will be entitled to receive an annual minimum royalty payment of $100,000 that will be credited toward the payment of royalties and sublicense fees otherwise payable to Hadasit during the calendar year. If Cell Cure Neurosciences or a sublicensee other than a Strategic Partner paid royalties during the previous year, Cell Cure Neurosciences may defer making the minimum royalty payment until December and will be obligated to make the minimum annual payment to the extent that royalties and sublicensing fee payments made during that year are less than $100,000.

If Cell Cure Neurosciences does not grant a sublicense to a Strategic Partner and Cell Cure Neurosciences or a sublicensee (other than a Strategic Partner) conducts clinical trials of OpRegen^®, Hadasit will be entitled to receive certain payments from Cell Cure Neurosciences upon the first attainment of certain clinical trial milestones in the process of seeking regulatory approval to market a product developed by Cell Cure Neurosciences using the licensed patents. Hadasit will receive $250,000 upon the completion of the enrollment of patients in the first Phase I clinical trial, $250,000 upon the submission of a report summarizing the Phase II clinical trial data to a regulatory agency as part of the approval process, and $1 million upon the enrollment of the first patient in the first Phase III clinical trial. These milestone payments are creditable by Cell Cure Neurosciences against sublicensing receipts that are payable to Hadasit at the time of each milestone payment for said milestone payment, except that the $1.0 million milestone payment shall only be creditable by Cell Cure Neurosciences if it received sublicensing receipts in excess of the amount of $50 million.

BioTime License for the University of Utah

BioTime acquired a license from the University of Utah to use certain patents in the production and sale of certain hydrogel products. BioTime will pay a 3% royalty on sales of products and services performed that utilize the licensed patents. Commencing in 2015, BioTime became obligated to pay minimum royalties to the extent that actual royalties on products sales and services utilizing the patents are less than the minimum royalty amount. The minimum royalty amounts were $2,500 in 2015 and will be $30,000 each year thereafter during the term of the License Agreement. BioTime shall also pay the University of Utah 30% of any sublicense fees or royalties received under any sublicense of the licensed patents.

BioTime will pay the University of Utah $5,000 upon the issuance of each of the first five licensed patents issued in the U.S., subject to reduction to $2,500 for any patent that the University has licensed to two or more other licensees for different uses. BioTime will also pay a $225,000 milestone fee within six months after the first sale of a “tissue engineered product” that utilizes a licensed patent. A tissue engineered product is defined as living human tissues or cells on a polymer platform, created at a place other than the point-of-care facility, for transplantation into a human patient.

Asterias License from WARF

Asterias has entered into a Non-Exclusive License Agreement with WARF under which Asterias was granted a worldwide non-exclusive license under certain WARF patents and WARF-owned embryonic stem cell lines to develop and commercialize therapeutic, diagnostic and research products. The licensed patents include patents covering primate embryonic stem cells as compositions of matter, as well as methods for growth and differentiation of primate embryonic stem cells. The licensed stem cell lines include the H1, H7, H9, H13 and H14 hES cell lines.

In consideration of the rights licensed, Asterias has agreed to pay WARF an upfront license fee, payments upon the attainment of specified clinical development milestones, royalties on sales of commercialized products, and, subject to certain exclusions, a percentage of any payments that Asterias may receive from any sublicenses that it may grant to use the licensed patents or stem cell lines.

The license agreement will terminate with respect to licensed patents upon the expiration of the last licensed patent to expire. Asterias may terminate the license agreement at any time by giving WARF prior written notice. WARF may terminate the license agreement if payments of earned royalties, once begun, cease for a specified period of time or if Asterias and any third parties collaborating or cooperating with Asterias in the development of products using the licensed patents or stem cell lines fail to spend a specified minimum amount on research and development of products relating to the licensed patents or stem cell lines for a specified period of time. WARF also has the right to terminate the license agreement if Asterias breaches the license agreement or becomes bankrupt or insolvent or if any of the licensed patents or stem cell lines are offered to creditors

Asterias License from the University of California

Geron Corporation (“Geron”) assigned to Asterias an Exclusive License Agreement with The Regents of the University of California for patents covering a method for directing the differentiation of multipotential hES cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytes for remyelination and treatment of spinal cord injury. Pursuant to this agreement, Asterias has an exclusive worldwide license under such patents, including the right to grant sublicenses, to create products for biological research, drug screening, and human therapy using the licensed patents. Under the license agreement, Asterias will be obligated to pay the university a royalty of 1% from sales of products that are covered by the licensed patent rights, and a minimum annual royalty of $5,000 starting in the year in which the first sale of a product covered by any licensed patent rights occurs, and continuing for the life of the applicable patent right under the agreement. The royalty payments due are subject to reduction, but not by more than 50%, to the extent of any payments that Asterias may be obligated to pay to a third party for the use of patents or other intellectual property licensed from the third party in order to make, have made, use, sell, or import products or otherwise exercise its rights under the Exclusive License Agreement. Asterias will be obligated to pay the university 7.5% of any proceeds, excluding debt financing and equity investments, and certain reimbursements, that its receives from sublicensees, other than Asterias’ affiliates and joint ventures relating to the development, manufacture, purchase, and sale of products, processes, and services covered by the licensed patent. The license agreement will terminate on the expiration of the last-to-expire of the university’s issued licensed patents. If no further patents covered by the license agreement are issued, the license agreement would terminate in 2024. The university may terminate the agreement in the event of Asterias’ breach of the agreement. Asterias can terminate the agreement upon 60 days’ notice.

Asterias Sublicense from Geron

Asterias has received from Geron an exclusive sublicense under certain patents owned by the University of Colorado’s University License Equity Holdings, Inc. relating to telomerase (the “Telomerase Sublicense”). The Telomerase Sublicense entitles Asterias to use the technology covered by the patents in the development of AST-VAC1 and AST-VAC2 as immunological treatments for cancer. Under the Telomerase Sublicense, Asterias paid Geron a one-time upfront license fee of $65,000, and will pay Geron an annual license maintenance fee of $10,000 due on each anniversary of the effective date of the Telomerase Sublicense, and a 1% royalty on sales of any products that Asterias may develop and commercialize that are covered by the sublicensed patents. The Telomerase Sublicense will expire concurrently with the expiration of Geron’s license. That license will terminate during April 2017 when the licensed patents expire. The Telomerase Sublicense may also be terminated by Asterias by giving Geron 90 days written notice, by Asterias or by Geron if the other party breaches its obligations under the sublicense agreement and fails to cure their breach within the prescribed time period, or by Asterias or by Geron upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other party.

OrthoCyte Agreements with Heraeus

OrthoCyte has entered into a License Agreement and a Research and Development Agreement with Heraeus for the development of innovative bone grafting therapies based on the use of our proprietary PureStem^® human embryonic progenitor cell technology. Pursuant to the terms of the Research and Development Agreement, OrthoCyte will carry out a research and development project aimed at producing a cell therapy bone grafting product, using PureStem^® technology and either HyStem^® scaffold technology for delivery of bioactives, referred to as the OrthoCyte Technology, or scaffold technology owned by Heraeus or licensed to it by third parties, referred to as the Heraeus Technology. The OrthoCyte Technology includes technology owned by it or BioTime or licensed from third parties.

Under the terms of the Research and Development Agreement, Heraeus agreed to make certain payments to OrthoCyte upon achieving certain milestones, and Heraeus will reimburse OrthoCyte for all costs and expenses incurred in connection with the project. Heraeus paid OrthoCyte an up-front payment of $1.0 million during 2015 which was not considered to be a substantive milestone payment and OrthoCyte will recognize this payment into revenues over the expected life of the agreement of 3.25 years. During the year ended December 31, 2015, $77,000 was recognized as revenues and the remaining amount is included in deferred revenues in our consolidated balance sheet as of December 31, 2015. Results of the project, including with respect to the product, that directly relate to the Heraeus Technology, or that incorporate or embody the Heraeus Technology in the product, will be owned by Heraeus, both within and outside the field of use, subject to OrthoCyte’s rights under the License Agreement. The Research and Development Agreement provides that OrthoCyte will manufacture the product, but would assist Heraeus in establishing a second manufacturing source if requested, in each case pursuant to a manufacturing and supply agreement to be negotiated between the parties.

The Research and Development Agreement is effective until the completion and payment of the last milestone set forth in the project plan, but may be terminated by either party immediately upon written notice to the other party if the other party fails to remedy any material breach of the agreement within 90 days following receipt of written notice of such breach. In addition, Heraeus may terminate the Research and Development Agreement (i) if the product is not merchantable or fit for use in the field of use, (ii) if a milestone cannot be fulfilled in the view of OrthoCyte, (iii) in the case either OrthoCyte’s or Heraeus’ technology used in the product infringes a third party’s intellectual property rights, or (iv) by written notice to OrthoCyte within 14 days following achievement of a milestone and payment to OrthoCyte of any milestone payments due.

Pursuant to the terms of the License Agreement, OrthoCyte has licensed the OrthoCyte Technology to Heraeus, and Heraeus has licensed the Heraeus Technology to OrthoCyte. The license grant by OrthoCyte to Heraeus is exclusive and worldwide in the field of bone grafting for all osteoskelton diseases and injuries, except oral maxilla-facial. The license grant by Heraeus to OrthoCyte is exclusive and worldwide in all other fields. Pursuant to the License Agreement, each of Heraeus and OrthoCyte will pay certain specified royalties to each other based on their respective net sales of the product developed in the research and development project. The License Agreement contains customary confidentiality obligations and representations and warranties. The License Agreement has a term expiring on the last to expire of the OrthoCyte patents licensed to Heraeus under the agreement, but may be terminated earlier (i) by Heraeus, at its sole discretion, on six months’ prior written notice or (ii) by either party for cause, such as default by the other party in any of its material obligations under the agreement which remains uncured for 60 days following written notice of the default, the other party challenges the intellectual property rights of the terminating party or the other party suffers an event of insolvency or bankruptcy. In addition, the License Agreement will terminate if the Research and Development Agreement is terminated prior to the launch of the product.

Amortization of Deferred License Fees

As of December 31, 2015, amortization of deferred license fees was as follows (in thousands):

Year Ended December 31,	Deferred License Fees
2016	$	148
2017		130
2018		84
2019		34
2020		13
Thereafter		61
Total	$	470

The current portion in the amount of $148,000 is included in prepaid expenses and other current assets and the noncurrent portion of $322,000 is included in deferred license fees.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost. During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias common stock to two investors for $12.5 million in cash. Broadwood Partners, L.P. (“Broadwood”), purchased 1,000,000 of the BioTime common shares with 1,000,000 Asterias warrants and a trust previously established by George Karfunkel purchased 4,000,000 of the BioTime common shares with 4,000,000 Asterias warrants. Asterias received $11.7 million when the warrants were exercised in May 2015. Broadwood is BioTime’s largest shareholder and one of its directors, Neal C. Bradsher, is President, and one of Asterias’ directors, Richard T. LeBuhn, is Senior Vice President, of Broadwood Capital, Inc., the investment manager of Broadwood. In February 2015, Asterias raised approximately $5.5 million in aggregate gross proceeds from the sale of 1,410,255 shares of its common stock at a price of $3.90 per share through an underwritten public offering and a private placement. Broadwood, British & American Investment Trust PLC, and Asterias’ Chief Executive Officer who was also a member of its Board of Directors purchased an aggregate of 1,025,640 of the shares. British & American Investment Trust PLC is an affiliate of a stockholder of Asterias and BioTime. In April and November 2015, Cell Cure Neurosciences issued certain convertible notes (the “Convertible Notes”) to a Cell Cure Neurosciences shareholder other than BioTime in the principal amount of $188,000 and $66,000, respectively. In July and September 2014, Cell Cure Neurosciences issued Convertible Notes to two Cell Cure Neurosciences shareholders other than BioTime in the principal amount of $471,000. One of the Cell Cure Neurosciences shareholders who acquired Convertible Notes is considered a related party. The functional currency of Cell Cure Neurosciences is the Israeli New Shekel, however the Convertible Notes are payable in United States dollars. The Convertible Notes bear a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Notes, with accrued interest, is due and payable on various maturity dates in July and September 2017. The outstanding principal balance of the Convertible Notes with accrued interest is convertible into Cell Cure Neurosciences ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Notes must be settled with Cell Cure Neurosciences ordinary shares and not with cash. The conversion feature of the Convertible Notes is not accounted for as an embedded derivative under the provisions of ASC 815, Derivatives and Hedging since it is not a freestanding financial instrument and the underlying Cell Cure Neurosciences ordinary shares are not readily convertible into cash. Accordingly, the Convertible Notes are accounted for under ASC 470-20, Debt with Conversion and Other Options. Under ASC 470-20, BioTime determined that a beneficial conversion feature (“BCF”) was present on the issuance dates of the Convertible Notes. A conversion feature is beneficial if, on the issuance dates, the effective conversion price is less than the fair value of the issuer’s capital stock. Since the effective conversion price of $20.00 per share is less than the estimated $41.00 per share fair value of Cell Cure Neurosciences ordinary shares on the dates the Convertible Notes were issued, a beneficial conversion feature equal to the intrinsic value is present. In accordance with ASC 470-20-30-8, if the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. The BCF is recorded as an addition to equity with a corresponding reduction to the carrying value of the convertible debt instrument. In the case of the Convertible Notes, this reduction represents a debt discount equal to the principal amount of $659,000 on the issuance dates. This debt discount will be amortized to interest expense using the effective interest method over the three-year term of the debt, representing an approximate effective annual interest rate of 23%. At December 31, 2015, the carrying value of the Convertible Notes was $324,000, comprised of principal and accrued interest of $748,000, net of unamortized debt discount of $424,000. In May 2015, OncoCyte entered into Subscription Agreements with two of its investors (the “Investors”) and BioTime (the “Subscription Agreements”). Under the Subscription Agreements, OncoCyte sold 3,000,000 shares of its common stock for $3.3 million in cash to the Investors, 1,000,000 shares of which were sold to George Karfunkel, a beneficial owner of more than 5% of the outstanding common shares of BioTime. In June 2015, after the sale of stock under the Subscription Agreements described above was completed, OncoCyte and the Investors entered into a second agreement. Under the second agreement, the Investors agreed that if on or before June 30, 2016 OncoCyte conducts another rights offering to its shareholders at a pre-offer valuation of at least $40.0 million the Investors will purchase shares in that offering with an aggregate purchase price equal to the lesser of (a) a percentage of total amount of capital which OncoCyte then seeks to raise in the rights offer and in any concurrent offering to third parties equal to the Investors’ aggregate pro rata share of the outstanding OncoCyte common stock on the record date for the rights offering, determined on a fully diluted basis, and (b) $3.0 million, or such lesser amount requested by OncoCyte. The Investors also agreed that, for a period of one year from the date of the second agreement, neither of them shall invest or engage, directly or indirectly, whether as a partner, equity holder, lender, principal, agent, affiliate, consultant or otherwise, in any business anywhere in the world that develops products for the diagnosis and treatment of cancer or otherwise competes with OncoCyte in any way; provided, however, that the passive ownership of less than 5% of the outstanding stock of any publicly-traded corporation will not be deemed, solely by reason thereof, to be in violation of that agreement. Under the second agreement, OncoCyte agreed that if shares of OncoCyte common stock were not publicly traded on any stock exchange or over the counter market by January 15, 2016, OncoCyte would issue to the Investors warrants to purchase, in the aggregate, 3,000,000 shares of OncoCyte common stock at an exercise price of $0.01 per share (see Note 12). For accounting purposes, the contingently issuable warrants, under the second agreement described above, were considered issued in June 2015 and classified as equity. OncoCyte estimated the issue date fair value of the warrants using a Black-Scholes valuation model and management estimate that there was a low probability of not satisfying the contingency and having to issue the warrants. Accordingly, the probability-adjusted, fair value of the warrants was $65,400 on the issuance date and recognized as a general and administrative expense, with a corresponding increase to common stock equity. OncoCyte common stock began trading on the NYSE MKT on a “when issued” basis on December 30, 2015 in connection with BioTime’s distribution of a portion of its OncoCyte shares to BioTime shareholders, extinguishing the contingent obligation to issue the warrants. In September 2015, BioTime sold 2,607,401 common shares at an offering price of $3.29 per share, for an aggregate purchase price of $8.6 million. Broadwood purchased 2,431,611 of the shares sold. The price per share was the closing price of the common shares on the NYSE MKT on September 11, 2015, the last trading day before BioTime and the investors entered into purchase agreements for the sale of the shares. In October 2015, BioTime sold 1,600,000 common shares to a shareholder for $5.1 million. The $3.19 price of price per share was the closing price of the common shares on the NYSE MKT on October 1, 2015, the last trading day before BioTime and the shareholder entered into a purchase agreement for the sale of the shares. In November 2015, BioTime paid approximately $267,000 in cash severance compensation to a former executive pursuant to the termination provisions included in his employment agreement, and expensed approximately $1.8 million in non-cash stock-based compensation for modifications to, and accelerated vesting of, stock options held by the former executive as of the termination date of his employment. In December 2015, certain BioTime board members invested in Ascendance as individual investors concurrently with BioTime’s investment in Ascendance as discussed in Note 12.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Shareholders' Equity

12 Months Ended

Dec. 31, 2015

Shareholders' Equity [Abstract]

Shareholders' Equity

9. Shareholders’ Equity

Preferred Shares

BioTime is authorized to issue 2,000,000 shares of preferred stock. The preferred shares may be issued in one or more series as the board of directors may by resolution determine. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. As of December 31, 2015, no shares of preferred stock were issued or outstanding.

In August 2015, to accommodate BioTime’s listing application to the Tel Aviv Stock Exchange (the “TASE”) BioTime and the BioTime preferred stock holders entered into a Preferred Stock Conversion Agreement (“PSCA”) whereby all of the 70,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”) were converted into BioTime common shares at a conversion price of $4.00 per share, a conversion ratio of 12.5 common shares for each share of Series A Preferred Stock. In connection with the PSCA BioTime delivered to the holders of the Series A Preferred Stock promissory notes for the net present value amount of the 3% dividends that the Series A Preferred Stock holders would have received if they held their shares of Series A Preferred Stock until March 4, 2019 (the mandatory conversion date under the terms of the Series A Preferred Stock) rather than converting those shares into common shares during August 2015. Payments of principal and interest on the promissory notes will be made semi-annually, from July 2015 through March 4, 2019. The issuance date fair value of the promissory notes was approximately $363,000, representing the net present value of cash payments to be made to the former preferred stock holders under the terms of the promissory notes.

In connection with the original issuance of the Series A Preferred Stock, BioTime entered into Option Agreements with the purchasers of the Series A Preferred Stock granting them the option to exchange shares of their Series A Preferred Stock for a portion of the shares of LifeMap Sciences common stock held by BioTime (“Original Option”). Pursuant to the PSCA, BioTime agreed that the former holders of Series A Preferred Stock may tender BioTime common shares in lieu of Series A Preferred Stock if they elect to exercise their option to acquire shares of LifeMap Sciences common stock from BioTime (“PSCA Option”).

BioTime accounted for the PSCA as an induced conversion of preferred stock in accordance with ASC 260-10-S99-2, Earnings Per Share – SEC Materials, and recorded a charge to equity for the aggregate fair value of $363,000 of promissory notes issued as additional consideration issued to the former preferred stock holders as part of the inducement offer. The option fair value to tender one BioTime common share in exchange for one share of LifeMap common stock was determined by BioTime to be immaterial to BioTime’s consolidated financial statements at the issuance date. The $363,000 charge to equity was included as dividends on preferred shares and increased net loss attributable to BioTime common shareholders on the consolidated statements of operations. BioTime performed a valuation of the Original Option and the PSCA Option and determined that there was no excess value between the fair value of the PSCA Option and the fair value of the Original Option on the conversion date.

Common shares

BioTime is authorized to issue 125,000,000 common shares with no par value. As of December 31, 2015, BioTime had 94,894,140 issued and 90,421,554 outstanding common shares. As of December 31, 2014, BioTime had 83,121,698 issued and 78,227,756 outstanding common shares. The difference of 4,472,586 and 4,893,942 common shares as of December 31, 2015 and 2014, respectively, is attributed to shares held by BioTime subsidiaries which are accounted for as treasury stock on the consolidated balance sheet.

Significant common share transactions during the year ended December 31, 2015 are as follows:

In September 2015, BioTime raised $8.6 million through the sale of 2,607,401 common shares at an offering price of $3.29 to three of its shareholders.

During October 2015, BioTime sold 6,530,612 common shares for $20.4 million in the aggregate to certain investment funds in Israel that hold shares of companies that are included within certain stock indexes of the TASE. The $3.13 purchase price per share was determined with reference to the closing price of BioTime common shares on the TASE on the date of sale. In addition, OncoCyte sold 246,356 BioTime common shares at the same price to one of the Israeli investment funds.

In October 2015, BioTime sold 1,600,000 common shares to a shareholder for $5.1 million. The $3.19 price of price per share was the closing price of the common shares on the NYSE MKT on October 1, 2015, the last trading day before BioTime and the shareholder entered into a purchase agreement for the sale of the shares.

During 2015 certain subsidiaries sold 175,000 BioTime common shares for gross proceeds of $615,000 at prevailing market prices through a broker-dealer acting as sales agent. The proceeds of the sale of BioTime shares by BioTime’s subsidiaries belong to those subsidiaries.

On December 31, 2015, BioTime distributed 4.7 million shares of OncoCyte common stock to its shareholders, on a pro rata basis, accounted for as a dividend in kind. On this date, BioTime shareholders received one share of OncoCyte common stock for every twenty shares of BioTime common stock held. As a result of this distribution, BioTime recorded a reduction in the carrying value of its investment in OncoCyte with a corresponding increase to noncontrolling interests in OncoCyte in the amount of $712,000, representing the reduction in BioTime’s ownership in OncoCyte by 18.7% from 76.5% to 57.8%. BioTime continues to hold a controlling financial interest in OncoCyte. This distribution generated a taxable gain of approximately $7.4 million to BioTime, however BioTime had sufficient current year losses to offset the entire gain (see Note 14).

Significant common share transactions during the year ended December 31, 2014 are as follows:

During 2014 BioTime and certain subsidiaries sold 5,545,160 BioTime common shares for gross proceeds of $17.4 million at prevailing market prices through a broker-dealer acting as sales agent. The proceeds of the sale of BioTime shares by BioTime’s subsidiaries belong to those subsidiaries.

During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias common stock to two investors for $12.5 million in cash.

During October 2014, BioTime sold 9,431,398 common shares for $29.4 million. The $3.12 price per share was the closing price of BioTime common shares on the NYSE MKT on the date on which BioTime and the investors agreed upon the purchase price.

BioTime has issued warrants to purchase its common shares. Activity related to warrants in 2015 and 2014 is presented in the table below (in thousands):

	Number of Warrants			Per share exercise price		Weighted Average Exercise Price
Outstanding, January 1, 2014		9,752		$	5.00 – 10.00	$	5.29
Exercised in 2014		(557	)		10.00		10.00
Outstanding, December 31, 2014		9,195		$	5.00	$	5.00
Exercised in 2015		(4	)		5.00		5.00
Warrant adjustment		919
Outstanding, December 31, 2015		10,110		$	4.55	$	4.55

At December 31, 2015, 10,109,860 warrants to purchase common shares with a weighted average exercise price of $4.55 per share and a weighted average remaining contractual life of 2.54 years were outstanding (see Note 18).

At December 31, 2014, 9,194,679 warrants to purchase common shares with a weighted average exercise price of $5.00 per share and a weighted average remaining contractual life of 3.42 years were outstanding (see Note 18).

See Note 10 for a summary of all option activity under the stock option plans of all subsidiaries for the years ended December 31, 2015 and 2014.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Stock Option Plans

12 Months Ended

Dec. 31, 2015

Stock Option Plans [Abstract]

Stock Option Plans

10. Stock Option Plans

During 2002, BioTime adopted the 2002 Employee Stock Option Plan (the “2002 Plan”), which was amended in 2004, 2007, and 2009 to reserve additional common shares for issuance under options or restricted stock awards granted to eligible persons. The 2002 Plan expired during September 2012 and no additional grants of options or awards of restricted stock may be made under the 2002 Plan.

During December 2012, BioTime’s Board of Directors approved the 2012 Equity Incentive Plan (the “2012 Plan”), which was amended during 2015, under which BioTime has reserved 10,000,000 common shares for the grant of stock options or the sale of restricted stock. No options may be granted under the 2012 Plan more than ten years after the date upon which the 2012 Plan was adopted by the Board of Directors, and no options granted under the 2012 Plan may be exercised after the expiration of ten years from the date of grant. Under the 2012 Plan, options to purchase common shares may be granted to employees, directors and certain consultants at prices not less than the fair market value at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. The 2012 Plan also permits BioTime to award restricted stock for services rendered or to sell common shares to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events under a restricted stock award agreement. BioTime may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares.

BioTime may also grant stock appreciation rights (“SARs”) and hypothetical units issued with reference to BioTime common shares (“Restricted Stock Units”) under the Plan. An SAR is the right to receive, upon exercise, an amount payable in cash or shares or a combination of shares and cash, as determined by the Board of Directors or the Compensation Committee, equal to the number of shares subject to the SAR that is being exercised multiplied by the excess of (a) the fair market value of a BioTime common share on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement.

The terms and conditions of a grant of Restricted Stock Units will be determined by the Board of Directors or Compensation Committee. No shares of stock will be issued at the time a Restricted Stock Unit is granted, and BioTime will not be required to set aside a fund for the payment of any such award. A recipient of Restricted Stock Units will have no voting rights with respect to the Restricted Stock Units. Upon the expiration of the restrictions applicable to a Restricted Stock Unit, BioTime will either issue to the recipient, without charge, one common share per Restricted Stock Unit or cash in an amount equal to the fair market value of one common share.

The following table summarizes stock-based compensation expense related to employee and director stock options awards for the years ended December 31, 2015, 2014, and 2013, which was allocated as follows (in thousands):

	Year Ended December 31,
	2015		2014		2013
Research and Development	$	3,267	$	1,310	$	830
General and Administrative		7,794		3,145		2,215
All stock-based compensation expense included in expenses	$	11,061	$	4,455	$	3,045

As of December 31, 2015, total unrecognized compensation costs related to unvested stock options under BioTime’s 2002 Plan and 2012 Plan was $10.1 million, which is expected to be recognized as expense over a weighted average period of approximately 6.73 years.

The table above does not include $173,100 of stock-based compensation to a consultant in 2013.

The weighted-average estimated fair value of stock options granted under BioTime’s 2002 Plan and 2012 Plan during the years ended December 31, 2015 and 2014 was $3.72 and $3.43 per share respectively, using the Black-Scholes Merton model with the following weighted-average assumptions:

	Year Ended December 31,
	2015		2014
Expected life (in years)		5.62		6.67
Risk-free interest rates		1.70%		2.19%
Volatility		65.82%		83.20%
Dividend yield		0.00%		0.00%

General Option Information

A summary of all option activity under BioTime’s 2002 Plan and 2012 Plan for the years ended December 31, 2015 and 2014 is as follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		2,315			4,567		$	2.71
Granted under 2012 Plan		(2,170	)		2,170			3.54
Exercised		-			(2,060	)		0.58
Forfeited/expired under 2002 Plan		-			(179	)		4.32
Forfeited/expired under 2012 Plan		523			(524	)		3.72
December 31, 2014		668			3,974		$	4.04
Increase in option pool		6,000			-			-
Granted under 2012 Plan		(1,650	)		1,650			3.72
Exercised		-			(156	)		4.00
Forfeited/cancelled/expired under 2002 Plan		-			(35	)		6.72
Forfeited/cancelled/expired under 2012 Plan		239			(239	)		3.82
December 31, 2015		5,257			5,194		$	3.93

Additional information regarding options outstanding under BioTime’s 2002 Plan and 2012 Plan as of December 31, 2015 is as follows (in thousands except exercise prices and weighted average exercise price):

			Options Outstanding				Options Exercisable

Range of Exercise Prices		Number Outstanding	Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price		Number Exercisable		Weighted Avg. Exercise Price
	2.52-3.96	3,196		7.08	$	3.53		1,165	$	3.47
	4.02-4.95	1,628		5.30	$	4.33		962	$	4.26
	5.02-8.58	370		1.13	$	6.12		361	$	6.15
	$2.52-8.58	5,194		6.10	$	3.93		2,488	$	4.16

Subsidiary Stock Option Plans

Asterias has adopted an Equity Incentive Plan that has substantially the same operative provisions as BioTime’s 2012 Plan except that it permits the sale or grant of up to 4,500,000 shares of Asterias common stock.

BioTime’s subsidiaries LifeMap Sciences, LifeMap Solutions, OncoCyte, OrthoCyte, ReCyte Therapeutics, and BioTime Asia have adopted stock option plans that have substantially the same operative provisions (the “Subsidiary Plans”). The LifeMap Sciences stock option plan authorizes the sale of up to 8,000,000 shares of LifeMap Sciences common stock, the LifeMap Sciences stock option plan authorizes the sale of up to 18,667 shares of LifeMap Solutions common stock, the OncoCyte stock option plan authorizes the sale of up to 2,000,000 shares of OncoCyte common stock, the BioTime Asia stock option plan authorizes the sale of up to 1,600 BioTime Asia ordinary shares, and the OrthoCyte and ReCyte Therapeutics stock option plans each authorize the sale of up to 4,000,000 shares of the applicable subsidiary’s common stock, through the exercise of stock options or under restricted stock purchase agreements. Cell Cure Neurosciences also has a stock option plan that authorizes the sale of 14,100 ordinary shares through the exercise of stock options.

No options may be granted under a Subsidiary Plan more than ten years after the date upon which the Subsidiary Plan was adopted by the subsidiary’s Board of Directors, and no options granted under a Subsidiary Plan may be exercised after the expiration of ten years from the date of grant. Under a Subsidiary Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of common stock at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the subsidiary’s Board of Directors or its Compensation Committee. Generally, subsidiary stock options have service related vesting conditions based on the continued performance of services for the subsidiary. The Subsidiary Plans also permit the subsidiaries to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. A subsidiary may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. To date, only stock options have been issued under the Subsidiary Plans.

A summary of Asterias’ Equity Incentive Plan activity follows (in thousands, except weighted average exercise price):

	Options and Restricted Stock Available for Grant			Number of Options and Restricted Stock Outstanding			Weighted Average Exercise Price
January 1, 2014		1,660			2,840		$	2.34
Options granted		(1,590	)		1,590			2.50
Restricted stock units issued		(400	)		200			2.34
Options exercised					(3	)		2.34
Options expired/forfeited		1,280			(1,280	)		2.34
December 31, 2014		950			3,347			2.42
Increase in option pool		3,500			-			-
Options granted		(2,005	)		2,005			3.81
Options exercised		-			(13	)		2.34
Options forfeited/cancelled		9			(9	)		3.22
Restricted stock vested					(200	)		2.34
Restricted stock units issued		(388	)		194			3.90
Restricted stock units vested					(145	)		3.90
Restricted stock units forfeited		1			(1	)		3.90
December 31, 2015		2,067			5,178		$	2.94

A summary of OncoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		1,250			2,750		$	0.76
Options forfeited/cancelled		28			(28	)		1.00
December 31, 2014		1,278			2,722			0.76
Increase in option pool		4,000			-			-
Options granted		(2,875	)		2,875			1.10
Options exercised		-			(6	)		0.67
Options forfeited/cancelled		1,121			(1,121	)		0.79
2 for 1 reverse stock split		(1,762	)		(2,235	)		2.02
Options granted after reverse stock split		(10	)		10			3.60
Options forfeited/cancelled after reverse stock split		5			(5	)		2.00
December 31, 2015		1,757			2,240		$	2.94

A summary of OrthoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		1,355		2,645		$	0.08
Options forfeited/cancelled		16		(16	)		0.07
December 31, 2015		1,371		2,629		$	0.08

(1)

There was no grant activity during 2014.

A summary of ReCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		2,710		1,290		$	2.05
Options forfeited/cancelled		11		(11	)		2.05
December 31, 2015		2,721		1,279		$	2.05

(1)

There was no grant activity during 2014.

A summary of LifeMap Sciences’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		413			1,929		$	1.49
Options forfeited/cancelled		58			(58	)		1.48
December 31, 2014		471			1,871			1.48
Options granted		(131	)		131			1.92
Options forfeited/cancelled		207			(207	)		1.79
December 31, 2015		547			1,795		$	1.47

A summary of LifeMap Solutions’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
Option pool added upon incorporation		19					$
Options granted		(13	)		13			500.00
December 31, 2014		6			13			500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		1			(1	)		500.00
December 31, 2015		5			14		$	500.00

BioTime Asia had 1,300 stock options available for future grants and 300 stock options outstanding, with a weighted average exercise price of $0.01 per share as of December 31, 2015.

Cell Cure Neurosciences had 1,860 stock options available for future grants and 12,240 stock options outstanding, with a weighted average exercise price of $23.93 per share as of December 31, 2015.

Sales of BioTime Common Shares by Subsidiaries	12 Months Ended
Sales of BioTime Common Shares by Subsidiaries	Dec. 31, 2015
Sales of BioTime Common Shares by Subsidiaries [Abstract]
Sales of BioTime Common Shares by Subsidiaries	11. Sales of BioTime Common Shares by Subsidiaries Certain BioTime subsidiaries hold BioTime common shares that the subsidiaries received from BioTime in exchange for capital stock in the subsidiaries. The BioTime common shares held by subsidiaries are treated as treasury stock by BioTime and BioTime does not recognize a gain or loss on the sale of those shares by its subsidiaries. During September 2015 certain BioTime subsidiaries sold 175,000 BioTime common shares for gross proceeds of $576,000 at the prevailing market price. The proceeds of the sale of BioTime shares by BioTime’s subsidiaries belong to those subsidiaries. During October 2015, OncoCyte sold 246,356 BioTime common shares for $771,094 to an Israeli investment funds at the prevailing market price (see Note 9). During June 2014, Asterias sold 5,000,000 of its BioTime common shares with warrants to purchase 5,000,000 shares of Asterias common stock to two investors for $12.5 million in cash (see Note 9).

Investment in Common Stock of Ascendance Biotechnology, Inc.	12 Months Ended
	Dec. 31, 2015
Investment in Common Stock of Ascendance Biotechnology, Inc. [Abstract]
Investment in Common Stock of Ascendance Biotechnology, Inc.	12. Investment in Common Stock of Ascendance Biotechnology, Inc. On December 9, 2015, BioTime acquired a 51.2% equity interest in the common stock of Ascendance Biotechnology, Inc. (“Ascendance”), in exchange for a group of assets and intellectual property licenses deemed to be a business, as defined by ASC 805, Business Combinations. Ascendance is a privately-held company that markets its drug assay tests for use in drug-development and safety-testing of products in the pharmaceutical and chemical industries and sells products for stem cell research. BioTime accounted for the Ascendance investment under the equity method of accounting since Ascendance is deemed a variable interest entity (VIE), and while BioTime is able to exercise significant influence over Ascendance, BioTime does not have a controlling financial interest nor is deemed to be the primary beneficiary of Ascendance. The acquisition date fair value of the Ascendance investment was $4.7 million and the carrying amount of the assets exchanged by BioTime was $1.0 million, resulting in a gain of $3.7 million recorded in other income or expenses, net, in the consolidated statements of operations in accordance with ASC 810-10-40. The acquisition date fair value of the Ascendance common stock was determined by using a combination of income and market valuation methods including company-specific discounted cash flows, guideline public companies and mergers and acquisitions methods, including consideration given to the issuance price of the Ascendance common stock to other noncontrolling shareholders for cash completed around the valuation date. BioTime’s share of net losses in the Ascendance investment recorded in the consolidated statements of operations between December 9, 2015 and December 31, 2015 was immaterial.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies

13. Commitments and Contingencies

BioTime had no fixed, non-cancelable contractual obligations as of December 31, 2015, with the exception of office and laboratory facility operating leases and capital leases for laboratory equipment.

BioTime Leases

On December 10, 2015, BioTime entered into a lease for approximately 30,795 square feet of rentable space in two buildings located in an office park in Alameda, California (the “New Alameda Lease”). The term of the New Alameda Lease is seven years and BioTime has an option to renew the term for an additional five years. The lease term will commence on the earlier of the date on which BioTime commences business operations in all or any portion of the leased premises, or June 1, 2016. BioTime moved into the New Alameda facility in February 2016 for the administrative areas of the facility and commenced the lease term (see Note 18). The landlord agreed to deliver possession of the leased premises, other than certain designated office space at one of the buildings, concurrently with execution of the New Alameda Lease, and to deliver possession of the designated office space to BioTime no later than February 1, 2016, in order for BioTime to complete construction of BioTime’s planned tenant improvements and to move into the leased premises.

The landlord will provide BioTime with an initial tenant improvement allowance of $1.4 million (the “Initial Allowance”) to be applied to the construction of improvements (costs to be pre-approved by the landlord) for the leased premises. The allowance may be increased by an additional amount of approximately $308,000 (the “Additional Allowance”), if BioTime so chooses (subject to landlord pre-approval of the costs). If BioTime does use any of the Additional Allowance, that amount will be amortized and repaid to the landlord with interest at a rate of 10% per annum, amortized on a monthly basis over the seven year term of the lease. Any unused balance of the Initial Allowance cannot be used against rent reduction and will expire unused.

BioTime is considered the owner of the tenant improvements under construction under ASC 840-40-55 as BioTime, among other things, has the primary obligation to pay for construction costs and BioTime will retain exclusive use of the building for its office and research facility requirements after construction is completed. In accordance with this guidance, amounts expended by BioTime for construction is reported as construction in progress, and the proceeds received from the landlord, if any, are reported as a liability. Upon the property being placed in service, BioTime will depreciate the property and the lease payments allocated to the landlord liability will be accounted for as debt service payments on that liability. BioTime had incurred approximately $93,000 of construction costs included in construction in progress and no significant amounts were reimbursable by the landlord as of December 31, 2015.

Total base lease payments under the New Alameda Lease per the lease agreement for the years ending December 31, is shown below (in thousands):

Years Ending December 31,	Minimum lease payments
2016	$	388
2017		789
2018		813
2019		837
2020		861
Thereafter		2,189
Total	$	5,877

In addition to base rent, BioTime will pay a pro rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to our leased space) and the landlord’s operating expenses, over the amounts of those expenses incurred by the landlord during 2016. As security for the performance of its obligations under the New Alameda Lease, BioTime provided the landlord with an initial security deposit of $846,862, which will be reduced by $423,431 after the first twenty-four months of the lease term, and further reduced by an additional $346,135 after the first thirty-six months of the lease term, by applying those amounts to future rent payment obligations under the lease, if BioTime is not in default under the Lease.

BioTime also currently pays $5,050 per month for the use of office space in New York City, which is made available to BioTime by one of its directors at his cost for use in conducting meetings and other business affairs.

Asterias Leases

On December 30, 2013, Asterias entered into a lease for an office and research facility located in Fremont, California, consisting of an existing building with approximately 44,000 square feet of space. The building is used by Asterias primarily to produce human embryonic stem cells and related products under current good manufacturing procedures (cGMP). Asterias constructed certain tenant improvements for its use at a cost of approximately $5.5 million, of which $4.4 million was paid by the landlord.

In January 2014, Asterias paid the landlord a $300,000 security deposit. The lease is for a term of 96 months that commenced on October 1, 2014, with two available five-year options to extend the term, upon one year notice by Asterias. During the first 15 months of the lease term, from October 1, 2014 through December 31, 2015, Asterias paid monthly base rent of $50,985 representing 22,000 square feet rather than 44,000 square feet. On January 1, 2016, base rent increased to $105,142 per month and will increase by approximately 3% annually on every October 1 thereafter.

Total base lease payments under the Fremont lease, including a fixed 3% management fee and 3% escalations, under the lease agreement for the years ending December 31, is shown below (in thousands):

Years Ending December 31,	Minimum lease payments
2016	$	1,271
2017		1,310
2018		1,347
2019		1,387
2020		1,430
Thereafter		2,604
Total	$	9,349

In addition to monthly base rent, Asterias will pay all real estate taxes, insurance and the cost of maintenance, repair and replacement of the leased premises. During the first 15 months of the lease term, Asterias was obligated to pay only 50% of the real estate taxes on the premises.

Asterias is considered the owner of the tenant improvements under construction under ASC 840-40-55 as Asterias, among other things, had the primary obligation to pay for construction costs and Asterias will retain exclusive use of the building for its office and research facility requirements after construction is completed. In accordance with this guidance, amounts previously expended by Asterias for construction were reported as construction in progress in Asterias’ financial statements, and the proceeds received from the landlord are reported as a liability. Upon the property being placed in service in December 2015, Asterias began to depreciate the property and the lease payments allocated to the landlord liability are accounted for as debt service payments on that liability. As of December 31, 2015, Asterias has incurred approximately $4.9 million of construction costs included in construction in progress, of which approximately $4.4 million reimbursable by the landlord is included in long term liabilities.

Asterias was provided access and rights to use the property beginning in March 2014 with “free-rent” until the lease payments commenced on October 1, 2014, as described above. Asterias commenced expensing rent beginning in March 2014 in accordance with ASC 840-20-25-10 and 11, Rent Expense During Construction. Accordingly, during the year ended December 31, 2015, Asterias has expensed approximately $1.3 million included in the statements of operations and a deferred rent balance of approximately $178,700 as of December 31, 2015, included in long-term liabilities.

Asterias also paid $3,512 per month for the use of approximately 120 square feet of the office space in New York City used to conduct meetings and other business affairs. The lease is for a term of one year commencing July 1, 2014.

Cell Cure Neurosciences Lease

Cell Cure Neurosciences leases approximately 290 square meters of office and laboratory space in Hadassah Ein Kerem, in Jerusalem, Israel under a lease that expires on November 30, 2016. Base monthly rent for that facility is approximately ILS 21,930 (approximately US$5,600). In addition to base rent, Cell Cure Neurosciences pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located. As of December 31, 2015 Cell Cure Neurosciences had a liability of ILS 36,000 (approximately US$9,000) in improvement costs. This amount is being amortized over 2.5 years.

LifeMap Leases

LifeMap Sciences leases approximately 104 square meters of office space in Tel Aviv, Israel under a lease expiring on June 19, 2016. Base monthly rent under the lease is ILS 7,280 (approximately US$1,800) per month. In addition to base rent, LifeMap Sciences pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located. LifeMap Sciences also leases several parking spots.

LifeMap Sciences leases approximately 120 square meters of office space in Hong Kong under a lease that commenced on December 1, 2015 and expires on May 31, 2016. Base monthly rent under the lease is HK$12,500 (approximately US $1,500) per month. In addition to base rent, LifeMap pays certain costs related to the operation of the building in which the leased premises are located.

LifeMap Sciences leases approximately 750 square feet of office space in Marshfield, Massachusetts under a lease that expires on September 30, 2018. Base monthly rent under the lease is approximately $1,217 per month.

LifeMap Sciences also leases approximately 200 square feet of office space in Hoboken, New Jersey under a lease that expires on February 28, 2018. Base monthly rent under the lease is $1,150 per month.

LifeMap Solutions leases approximately 386 square feet of office space in San Jose, California under a lease that expires on May 31, 2016. Base monthly rent under the lease is $5,458 per month.

Rent expenses totaled $2.1 million, $2.0 million, and $1.6 million for the years ended December 31, 2015, 2014, and 2013, respectively. Remaining minimum annual lease payments under the various operating leases for the years ending after December 31, 2015 are as follows (in thousands):

Year Ending December 31,	Minimum lease payments
2016	$	2,070
2017		2,155
2018		2,186
2019		2,224
2020		2,292
Thereafter		4,792
Total	$	15,719

Employment Agreements

BioTime and its subsidiaries are party to certain employment agreements that provide for the provision of cash compensation and other benefits upon a “change in control,” which may include an acquisition of BioTime or substantially all of its assets, or upon termination of employment without “cause “ or for “good reason” as defined in the employment agreements.

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Income Taxes

14. Income Taxes

The primary components of the deferred tax assets and liabilities at December 31, 2015 and 2014 were as follows (in thousands):

Deferred tax assets/(liabilities):	2015			2014
Net operating loss carryforwards	$	78,268		$	58,693
Research & development and other credits		8,331			5,230
Patents and licenses		(6,860	)		(8,153	)
Equity method investment gain		(1,333	)		-
Stock options		670			1,561
Other, net		(263	)		(1	)
Total		78,813			57,329
Valuation allowance		(78,813	)		(61,844	)
Net deferred tax liabilities	$	-		$	(4,515	)

Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:

	Year Ended December 31,
	2015			2014			2013
Computed tax benefit at federal statutory rate		34	%		34	%		34	%
Research & development and other credits		2	%		3	%		-
Permanent differences		(4	%)		(1	%)		(15	%)
Losses for which no benefit has been recognized		(34	%)		(24	%)		(18	%)
State tax benefit, net of effect on federal income taxes		10	%		3	%		4	%
Foreign rate differential		(1	%)		(1	%)		1	%
		7	%		14	%		6	%

As of December 31, 2015, BioTime has net operating loss carryforwards of approximately $166.1 million for federal and $105.3 million for state tax purposes, which expire in varying amounts between 2016 and 2035. In addition, as of December 31, 2015 BioTime has research tax credit carryforwards for federal and state tax purposes of $4.1 million and $4.2 million, respectively. The federal tax credits expire between 2018 and 2035, while the state tax credits have no expiration date. As of December 31, 2015, BioTime’s subsidiaries have foreign net operating loss carryforwards of approximately $59.7 million which carry forward indefinitely.

A deferred income tax benefit of $4.5 million was recorded for the year ended December 31, 2015, of which $4.8 million was related to the federal benefit and $290,000 was related to state tax expense. A deferred income tax benefit of $7.4 million was recorded for the year ended December 31, 2014, of which $5.2 million of the benefit was related to federal and $2.2 million was related to state taxes. This deferred tax benefit was wholly attributable to BioTime’s majority owned and consolidated subsidiary, Asterias. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Except as disclosed above for Asterias, BioTime established a valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. Asterias established deferred tax liabilities primarily related to its acquisition of certain intellectual property. It is more likely than not that the Asterias deferred tax assets are fully realizable since these income tax benefits are expected to be available to offset such Asterias deferred tax liabilities. As BioTime and Asterias file separate U.S. federal tax returns, they may not use each other's tax attributes. Accordingly, BioTime has established a valuation allowance only pertaining to its deferred tax assets presented in the consolidated balance sheet as of December 31, 2015 and 2014.

In June 2014, Asterias sold 5,000,000 BioTime shares that resulted in a taxable gain of approximately $10.3 million. Asterias received the BioTime shares from BioTime as part of the consideration for the Asterias common stock and warrants issued to BioTime under an Asset Contribution Agreement among BioTime, Asterias, and Geron Corporation, in a tax free transaction. This taxable gain was offset by available net operating losses, resulting in no income taxes due from the sale.

During 2015 and 2014, OncoCyte sold 259,712 and 406,756 BioTime common shares, respectively, in open market transactions that resulted in a taxable gain of $815,000 and $1.3 million respectively. This taxable gain was fully offset by current operating losses resulting in no income taxes due from the sale. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. OncoCyte established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

On December 31, 2015, BioTime distributed 4.7 million shares of OncoCyte common stock to its shareholders on a pro rata basis. The distribution was accounted for as a dividend in kind for financial reporting purposes (see Note 9). For income tax purposes, the distribution is treated as if BioTime had sold the shares at their fair market value, resulting in a taxable gain to BioTime of approximately $7.4 million. As the distribution was treated as a dividend in kind for financial reporting purposes, BioTime recorded the tax effect of the gain in equity instead of the tax provision in accordance ASC 740-20-45-11(g). BioTime has sufficient current year losses from operations to offset the entire taxable gain resulting in no income taxes due.

As part of the above distribution of OncoCyte common stock, Asterias, as it also holds BioTime common stock, received 192,644 shares of OncoCyte common stock resulting in a taxable gain to Asterias of $819,000. Asterias has sufficient current year losses from operations to offset the entire taxable gain resulting in no income taxes due. As the distribution was treated as a dividend in kind for financial reporting purposes, the tax effect of this gain was recorded in equity instead of the tax provision consistent with BioTime’s treatment of the distribution.

In connection with the above transactions related to the taxable gains, BioTime and subsidiaries utilized approximately $9.1 million in net operating loss carryforwards with a corresponding release of the valuation allowance recorded through equity in accordance with ASC 740-20-45-11(g).

Internal Revenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by net operating loss (“NOL”) carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods.

BioTime files a U.S. federal income tax return as well as various state and foreign income tax returns. In general, BioTime is no longer subject to tax examination by major taxing authorities for years before 2011. Although the statute is closed for purposes of assessing additional income and tax in these years, the taxing authorities may still make adjustments to the net operating loss and credit carryforwards used in open years. Therefore the statute should be considered open as it relates to the net operating loss and credit carryforwards.

BioTime's practice is to recognize interest and penalties related to income tax matters in tax expense. As of December 31, 2015, BioTime has no accrued interest and penalties. BioTime may be subject to potential examination by U.S. federal, U.S. states or foreign jurisdiction authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. BioTime's management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Segment Information	12 Months Ended
Segment Information	Dec. 31, 2015
Segment Information [Abstract]
Segment Information	15. Segment Information BioTime’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, BioTime’s executive management team has viewed BioTime’s operations as one segment that includes, the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery, and products for human embryonic stem cell research. As a result, the financial information disclosed materially represents all of the financial information related to BioTime’s sole operating segment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Enterprise-wide Disclosures

12 Months Ended

Dec. 31, 2015

Enterprise wide Disclosures [Abstract]

Enterprise-wide Disclosures

16. Enterprise-wide Disclosures

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor. (In thousands)

	Revenues for the Year ending December 31,
Geographic Area	2015			2014			2013
Domestic		$	5,976		$	3,586		$	2,106
Asia			1,060			1,658			2,328
Total revenues		$	7,036		$	5,244		$	4,434

Major Sources of Revenues

BioTime has two major customers and three major grants comprising significant amounts of total revenues.

Most of BioTime’s royalty revenues were generated through sales of Hextend^® by Hospira in the U.S. and by CJ Health in the Republic of Korea. Hospira was purchased by Pfizer, Inc. in February 2015. BioTime also earned license fees from CJ Health. During 2015 Asterias also received royalty revenues from product sales from a non-exclusive license agreement with Stem Cell Technologies, Inc.

During September 2011, the National Institutes of Health (“NIH”) awarded BioTime a $336,000 research grant (the “2011 NIH Grant”). During 2014, BioTime received $117,000, and recognized as revenues $110,000 under the 2011 NIH Grant. The grant period commenced on September 30, 2011 and ended on September 29, 2014.

During 2013, the NIH also awarded BioTime a separate research contract in the amount of $285,000 (the “2013 NIH Contract”). During 2015 and 2014, BioTime received $214,000, and recognized as revenues $110,000 under the 2013 NIH Contract. The 2013 NIH Contract period ended on September 4, 2014.

During 2014, the NIH awarded BioTime three research and development grants.

•

One grant was for $270,262 (the “2014 NIH Grant #1”). During 2015 and 2014, BioTime received $199,000 and $72,000, respectively and recognized as revenues $143,000 and $128,000, respectively under the 2014 NIH Grant #1. The 2014 NIH Grant #1 period ended on August 31, 2015.

•

A second NIH grant was for $292,262 (the “2014 NIH Grant #2”). During 2015 and 2014, BioTime received $227,000 and $65,000, respectively and recognized as revenues $175,000 and $117,000, respectively under the 2014 NIH Grant #2. The 2014 NIH Grant #2 period ended on August 31, 2015.

•

The third NIH grant was for $224,911 (the “2014 NIH Grant #3”). During 2015 and 2014, BioTime received $161,000 and $64,000, respectively and recognized as revenues $138,000 and $87,000, respectively under the 2014 NIH Grant #3. The 2014 NIH Grant #3 period ended in November 2015.

During 2015 and 2014, grant income also included $3.8 million and $2.6 million, respectively, from grants awarded to certain BioTime subsidiaries. BioTime recognized $2.7 million and $1.0 million, of grant income during 2015 and 2014, respectively, through Asterias under a $14.3 million grant from CIRM. BioTime recognized $1.0 million and $1.6 million of grant income, respectively, through Cell Cure Neurosciences from certain grants, largely from the Office of the Chief Scientist of Israel (“OCS”).

During 2015, BioTime received $1,357,000 and recognized $679,000 (net of $678,000 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences. During 2014, BioTime received $1.0 million and recognized $621,000 (net of $552,000 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences.

The following table shows the relative portions of BioTime’s royalty and license fee revenues paid by Hospira, CJ Health, and Summit Pharmaceuticals International Corporation (“Summit”) that were recognized during the years ended December 31, 2015, 2014, and 2013, subscription and advertisement revenues, and grant income recognized during the same periods with respect to grants provided by OCS, the NIH and CIRM:

	Revenues for the Year ending December 31,
Sources of Revenues	2015		2014		2013
Hospira		2.0%		3.0%		6.5%
CJ Health		0.3%		1.0%		1.7%
GE Health		4.8%		-%		-%
Summit⁽¹⁾		-%		-%		20.3%
CIRM		42.7%		19.7%		-%
NIH		6.5%		12.5%		5.0%
OCS		14.4%		31.3%		27.9%
Subscription and Advertising (various customers)		29.4%		32.5%		38.6%

(1)

BioTime recognized the unamortized balance of the Summit license fees during the fourth quarter of 2013 as a result of the termination of its license agreements with Summit.

Selected Quarterly Financial Information (UNAUDITED)

12 Months Ended

Dec. 31, 2015

Selected Quarterly Financial Information (UNAUDITED) [Abstract]

Selected Quarterly Financial Information (UNAUDITED)

17. Selected Quarterly Financial Information (UNAUDITED, in thousands, except per share data)

BioTime has derived this data from the unaudited consolidated interim financial statements that, in BioTime’ s opinion, have been prepared on substantially the same basis as the audited consolidated financial statements contained in this report and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited quarterly results should be read in conjunction with the financial statements and notes thereto included in this report. The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period.

Year Ended December 31, 2015	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Revenues, net	$	1,000		$	1,749		$	1,874		$	1,306
Operating expenses		14,502			15,245			18,978			23,013
Loss from operations		(13,502	)		(13,496	)		(17,104	)		(21,707	)
Net loss attributable to BioTime, Inc.⁽¹⁾		(10,167	)		(9,691	)		(13,626	)		(13,507	)

Basic and diluted net loss per share	$	(0.13	)	$	(0.12	)	$	(0.18	)	$	(0.16	)

Year Ended December 31, 2014
Revenues, net	$	935		$	855		$	960		$	1,657
Operating expenses		12,073			13,917			13,098			16,001
Loss from operations		(11,138	)		(13,062	)		(12,138	)		(14,345	)
Net loss attributable to BioTime, Inc.⁽¹⁾		(8,099	)		(9,520	)		(8,268	)		(10,525	)

Basic and diluted net loss per share	$	(0.14	)	$	(0.16	)	$	(0.12	)	$	(0.14	)

(1)

Net of $4.5 million and $7.4 million of deferred income tax benefits for 2015 and 2014 respectively.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events In January 2016, the Board of Directors of BioTime adjusted the number of BioTime common shares (“Warrant Shares”) that may be purchased upon the exercise of each outstanding BioTime common share purchase warrant, and the purchase price payable for each Warrant Share (the “Warrant Price”), as a result of BioTime’s distribution of 4,744,707 shares of common stock, no par value, of BioTime’s subsidiary OncoCyte to BioTime shareholders on December 31, 2015. The adjusted number of Warrant Shares that may be purchased through exercise of each warrant is 1.1 shares. The adjusted Warrant Price is $4.55 per Warrant Share. On January 22, 2016, OncoCyte entered into a License Agreement with The Wistar Institute of Anatomy and Biology (“Wistar”). Under the License Agreement, OncoCyte has obtained an exclusive, worldwide license under certain patents, and under certain know-how and data (“Technical Information”) belonging to Wistar, for use in the field of molecular diagnostics for lung cancer, including, but not limited to confirmatory, companion and recurrence diagnostics for any type of lung cancer with detection through whole blood, fractionated blood, plasma, serum and/or other biological samples (the “Licensed Field”). OncoCyte has the right to grant sublicenses of the licensed patents and Technical Information. The sublicensee will be subject to Wistar’s approval, which will not be unreasonably withheld, if OncoCyte is not selling a “Licensed Product.” As used in the License Agreement, a Licensed Product means any product that cannot be made, used, or sold, or any service, process or method that cannot be performed or provided, without infringing at least one pending or issued valid claim under the licensed patents in a particular country, or that incorporates or is made, identified, developed, optimized, characterized, selected, derived or determined to have utility, in whole or in part, by the use or modification of any licensed patent or any technology or invention covered thereby, any licensed Technical Information, or any other Licensed Product. OncoCyte has paid Wistar an initial license fee and will pay Wistar royalties on net sales, as defined in the License Agreement, of Licensed Products. The royalty rates will range from 3% to 5% depending upon the amount of cumulative net sales of Licensed Products. If OncoCyte is required to pay to royalties to a third party in order to manufacture or sell a Licensed Product in a particular country, the amount of royalties that OncoCyte must pay Wistar on net sales of the Licensed Product will be reduced by the amount of royalties that OncoCyte must pay to the third party, but subject to a maximum reduction of 50%. OncoCyte’s obligation to pay royalties to Wistar will terminate on a Licensed Product by-Licensed Product and country-by-country basis until the later of (i) the date a valid claim of a licensed patent covering the Licensed Product no longer exists, or (ii) the tenth (10th) anniversary of the first commercial sale of the Licensed Product in each country. OncoCyte will pay Wistar a minimum annual royalty during each subsequent year, which in each case will be credited against total royalties due on net sales of Licensed Products during the year in which the minimum royalty is paid. OncoCyte will also be obligated to pay Wistar an annual license maintenance fee each year unless OncoCyte initiates sales of at least one Licensed Product by January 1, 2018. In addition to royalties on net sales, if OncoCyte grants any sublicense to the licensed patents or Technical Information, it will pay Wistar a portion of any non-royalty sublicensing income that it may receive from the sublicensee. Non-royalty sublicensing income will include any consideration OncoCyte receives from a sublicensee for granting the sublicense, but excluding royalties on net sales of Licensed Products, the fair market value of any equity or debt securities OncoCyte may sell to a sublicensee, and any payments OncoCyte may receive from a sublicensee for research of a Licensed Product that OncoCyte may conduct. OncoCyte also will pay Wistar (a) milestone payments upon the occurrence of certain milestone events in the development and commercialization of a Licensed Product, and (b) all past or ongoing costs incurred or to be incurred by Wistar, including government fees and attorneys’ fees, in the course of prosecuting the licensed patents. OncoCyte has agreed to use commercially reasonable diligent efforts, directly or through sublicensees, to develop and commercialize License Products. OncoCyte will provide Wistar with written plans for the development and commercialization of License Products and Wistar has the right to raise reasonable objections to those plans. OncoCyte will also provide Wistar with annual reports on progress in developing, evaluating, testing, and commercializing Licensed Products. OncoCyte has agreed that it or a sublicensee will commence commercial sale of a Licensed Product by a specified date. If sales of a Licensed Product do not commence by the specified date, OncoCyte may purchase up to three one-year extensions of the deadline by paying Wistar a designated fee for the applicable extension. OncoCyte has agreed to indemnify Wistar and its trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel and staff (the “Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense (including attorney’s fees) suffered or incurred by the Indemnified Parties due to claims which result from or arise out of (a) the License Agreement and the license granted to OncoCyte, and any sublicense granted pursuant to the License Agreement, (b) the development, use, manufacture, promotion, sale or other disposition of the licensed patents, licensed Technical Information or any Licensed Products, (c) the breach of any of OncoCyte’s representations, warranties, or covenants in the License Agreement, or a breach of a sublicense by a sublicensee, or (d) the successful enforcement by an Indemnified Party of its indemnification rights under the License Agreement. This indemnification obligation shall apply to liabilities resulting from: (i) any product liability or other claim of any kind related to the use of a Licensed Product; (ii) any claim that the licensed patents or the design, composition, manufacture, use, sale or other disposition of any Licensed Product infringes or violates any patent, copyright, trademark or other intellectual property rights of any third party; or (iii) clinical trials or studies conducted by or on behalf of OncoCyte or any sublicensee relating to the Licensed Products. Notwithstanding the foregoing, OncoCyte will not be obligated to indemnify and hold harmless the Indemnified Parties from and against any liabilities that result from or arise out of an Indemnified Party’s gross negligence or willful misconduct. On February 16, 2016, BioTime began operating from the leased space under the New Alameda Lease. As of the date of this report, certain parts of the facility are still under construction and subject to landlord reimbursements as discussed in Note 13. On February 29, 2016, Asterias appointed a new Chief Executive Officer (the “Executive) and as member of the Board of Directors of Asterias (the "Board"). Asterias and the Executive entered into an employment agreement (the "Employment Agreement"), which provides for an annual base salary of $452,400, a grant of stock options to purchase 1,000,000 shares Asterias common stock at an exercise price of $3.64 per share, and a grant of 200,000 restricted shares of Asterias common stock. Subject the Executive’s continued employment with Asterias, the stock options vest in equal monthly installments over 48 months commencing on March 31, 2016, and 50% of the restricted stock vests on August 31, 2016 and February 28, 2017. In addition, the Executive is eligible for an annual Bonus Opportunity up to 50% of his base salary (the "Bonus Opportunity"). Asterias’ Board, or its Compensation Committee, has absolute discretion in determining whether and to what extent any payment under the Bonus Opportunity are to be made based on performance criteria that the Board, or its Compensation Committee, may determine from time to time. The Executive’s employment agreement contains provisions entitling him to severance benefits under certain circumstances. If Asterias terminates the Executive’s employment without "Cause" or if he resigns for "Good Reason" otherwise than within 12 months following a "Change of Control") as those terms are defined in the Employment Agreement, he will be entitled to severance benefits. If the Executive has been employed by Asterias for one year or less, his severance benefits will be include payment of six months base salary and 50% of the Executive’s Bonus Opportunity. If the Executive is employed with Asterias for more than one year, his severance benefits will include payment of 12 months base salary, 100% of his Bonus Opportunity, accelerated vesting of all unvested restricted stock previously granted, and accelerated vesting of 50% of unvested stock options previously granted. If the Executive’s employment is terminated without "Cause" or if he resigns for "Good Reason" within twelve months within a Change of Control, his severance benefits will be include payment of 100% of his base salary, 100% of the Bonus Opportunity, and accelerated vesting of all unvested restricted stock and stock options previously granted.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Revenue recognition

Cash and cash equivalents

Cash and cash equivalents – BioTime considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Trade accounts and grants receivable, net

Concentrations of credit risk

Fair value measurements

●

Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

●

Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.

Available for sale securities in foreign investments

Fair value of financial instruments

Inventory

Investments in Common Stock of Privately Held Companies

Equipment, net and construction in progress

Intangible assets, net

Treasury stock

Warrants to purchase common stock

Cost of sales

Patent costs

Patent costs – Costs associated with obtaining patents on products or technology developed are expensed as research and development expenses when incurred.

Reclassification

Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation.

Research and development

General and administrative

Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses

Income taxes

Stock-based compensation

Impairment of long-lived assets

Deferred license fees

Loss per share

Recently Issued Accounting Pronouncements

Organization, Basis of Presentation and Liquidity (Tables)

12 Months Ended

Dec. 31, 2015

Organization, Basis of Presentation and Liquidity [Abstract]

BioTime's ownership of outstanding shares of its subsidiaries

The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of December 31, 2015.

Subsidiary	Field of Business	BioTime Ownership	Country
Asterias Biotherapeutics, Inc.	Human therapeutic products from stem cells, focused initially in the fields of neurology and oncology	57.1%	USA
Cell Cure Neurosciences Ltd.	Products to treat age-related macular degeneration	62.5%⁽¹⁾	Israel
ES Cell International Pte Ltd	Stem cell products for research, including clinical grade cell lines produced under cGMP	100%	Singapore
LifeMap Sciences, Inc.	Biomedical, gene, disease, and stem cell databases and tools	77.9%	USA
LifeMap Sciences, Ltd.	Biomedical, gene, disease, and stem cell databases and tools	(2)	Israel
LifeMap Solutions, Inc.	Mobile health software	(2)	USA
OncoCyte Corporation	Cancer diagnostics	57.7%	USA
OrthoCyte Corporation	Developing bone grafting products for orthopedic diseases and injuries	100%	USA
ReCyte Therapeutics, Inc.	Research and development involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders, ischemic conditions and brown adipocytes for type-2 diabetes and obesity	94.8%	USA

(1)

Includes shares owned by BioTime, Asterias and ESI.

(2)

LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.

Equipment, net and construction in progress (Tables)

12 Months Ended

Dec. 31, 2015

Equipment, net and construction in progress [Abstract]

Equipment, furniture and fixtures, and construction in progress

At December 31, 2015 and 2014, equipment, furniture and fixtures, and construction in progress were comprised of the following (in thousands):

	2015			2014
Equipment, furniture and fixtures	$	10,757		$	4,871
Construction in progress		93			406
Accumulated depreciation		(3,311	)		(2,419	)
Equipment, net and construction in progress	$	7,539		$	2,858

Intangible assets, net (Tables)

12 Months Ended

Dec. 31, 2015

Intangible assets, net [Abstract]

Intangible assets

At December 31, 2015 and 2014, intangible assets and accumulated intangible assets were comprised of the following (in thousands):

	2015			2014
Intangible assets	$	52,563		$	52,562
Accumulated amortization		(18,971	)		(13,714	)
Intangible assets, net	$	33,592		$	38,848

Intangible assets future amortization expense

Amortization of intangible assets for periods subsequent to December 31, 2015 is as follows (in thousands):

Year Ended December 31,	Amortization Expense
2016	$	5,256
2017		5,256
2018		5,256
2019		5,256
2020		4,480
Thereafter		8,088
Total	$	33,592

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2015

Shareholders' Equity [Abstract]

Activity related to warrants

BioTime has issued warrants to purchase its common shares. Activity related to warrants in 2015 and 2014 is presented in the table below (in thousands):

	Number of Warrants			Per share exercise price		Weighted Average Exercise Price
Outstanding, January 1, 2014		9,752		$	5.00 – 10.00	$	5.29
Exercised in 2014		(557	)		10.00		10.00
Outstanding, December 31, 2014		9,195		$	5.00	$	5.00
Exercised in 2015		(4	)		5.00		5.00
Warrant adjustment		919
Outstanding, December 31, 2015		10,110		$	4.55	$	4.55

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Stock Option Plans (Tables)

12 Months Ended

Dec. 31, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of stock option activity

	Year Ended December 31,
	2015		2014		2013
Research and Development	$	3,267	$	1,310	$	830
General and Administrative		7,794		3,145		2,215
All stock-based compensation expense included in expenses	$	11,061	$	4,455	$	3,045

Schedule of weighted average assumptions to calculate fair value of stock options

	Year Ended December 31,
	2015		2014
Expected life (in years)		5.62		6.67
Risk-free interest rates		1.70%		2.19%
Volatility		65.82%		83.20%
Dividend yield		0.00%		0.00%

Additional information regarding options outstanding

			Options Outstanding				Options Exercisable

Range of Exercise Prices		Number Outstanding	Weighted Avg. Remaining Contractual Life (years)		Weighted Avg. Exercise Price		Number Exercisable		Weighted Avg. Exercise Price
	2.52-3.96	3,196		7.08	$	3.53		1,165	$	3.47
	4.02-4.95	1,628		5.30	$	4.33		962	$	4.26
	5.02-8.58	370		1.13	$	6.12		361	$	6.15
	$2.52-8.58	5,194		6.10	$	3.93		2,488	$	4.16

2002 Plan and 2012 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of stock option activity

A summary of all option activity under BioTime’s 2002 Plan and 2012 Plan for the years ended December 31, 2015 and 2014 is as follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		2,315			4,567		$	2.71
Granted under 2012 Plan		(2,170	)		2,170			3.54
Exercised		-			(2,060	)		0.58
Forfeited/expired under 2002 Plan		-			(179	)		4.32
Forfeited/expired under 2012 Plan		523			(524	)		3.72
December 31, 2014		668			3,974		$	4.04
Increase in option pool		6,000			-			-
Granted under 2012 Plan		(1,650	)		1,650			3.72
Exercised		-			(156	)		4.00
Forfeited/cancelled/expired under 2002 Plan		-			(35	)		6.72
Forfeited/cancelled/expired under 2012 Plan		239			(239	)		3.82
December 31, 2015		5,257			5,194		$	3.93

Asterias Biotherapeutics [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of Asterias’ Equity Incentive Plan activity follows (in thousands, except weighted average exercise price):

	Options and Restricted Stock Available for Grant			Number of Options and Restricted Stock Outstanding			Weighted Average Exercise Price
January 1, 2014		1,660			2,840		$	2.34
Options granted		(1,590	)		1,590			2.50
Restricted stock units issued		(400	)		200			2.34
Options exercised					(3	)		2.34
Options expired/forfeited		1,280			(1,280	)		2.34
December 31, 2014		950			3,347			2.42
Increase in option pool		3,500			-			-
Options granted		(2,005	)		2,005			3.81
Options exercised		-			(13	)		2.34
Options forfeited/cancelled		9			(9	)		3.22
Restricted stock vested					(200	)		2.34
Restricted stock units issued		(388	)		194			3.90
Restricted stock units vested					(145	)		3.90
Restricted stock units forfeited		1			(1	)		3.90
December 31, 2015		2,067			5,178		$	2.94

OrthoCyte Corporation [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of OncoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		1,250			2,750		$	0.76
Options forfeited/cancelled		28			(28	)		1.00
December 31, 2014		1,278			2,722			0.76
Increase in option pool		4,000			-			-
Options granted		(2,875	)		2,875			1.10
Options exercised		-			(6	)		0.67
Options forfeited/cancelled		1,121			(1,121	)		0.79
2 for 1 reverse stock split		(1,762	)		(2,235	)		2.02
Options granted after reverse stock split		(10	)		10			3.60
Options forfeited/cancelled after reverse stock split		5			(5	)		2.00
December 31, 2015		1,757			2,240		$	2.94

A summary of OrthoCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		1,355		2,645		$	0.08
Options forfeited/cancelled		16		(16	)		0.07
December 31, 2015		1,371		2,629		$	0.08

(1)

There was no grant activity during 2014.

ReCyte Therapeutics, Inc. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of ReCyte’s Stock Option Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant		Number of Options Outstanding			Weighted Average Exercise Price
December 31, 2014⁽¹⁾		2,710		1,290		$	2.05
Options forfeited/cancelled		11		(11	)		2.05
December 31, 2015		2,721		1,279		$	2.05

(1)

There was no grant activity during 2014.

LifeMap Sciences, Inc. [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of LifeMap Sciences’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
January 1, 2014		413			1,929		$	1.49
Options forfeited/cancelled		58			(58	)		1.48
December 31, 2014		471			1,871			1.48
Options granted		(131	)		131			1.92
Options forfeited/cancelled		207			(207	)		1.79
December 31, 2015		547			1,795		$	1.47

LifeMap Solutions, Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedule of share-based compensation, employee stock purchase plan, activity

A summary of LifeMap Solutions’ Equity Incentive Plan activity follows (in thousands except weighted average exercise price):

	Options Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
Option pool added upon incorporation		19					$
Options granted		(13	)		13			500.00
December 31, 2014		6			13			500.00
Options granted		(2	)		2			500.00
Options forfeited/cancelled		1			(1	)		500.00
December 31, 2015		5			14		$	500.00

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies [Abstract]

Base rent under New Alameda lease

Total base lease payments under the New Alameda Lease per the lease agreement for the years ending December 31, is shown below (in thousands):

Years Ending December 31,	Minimum lease payments
2016	$	388
2017		789
2018		813
2019		837
2020		861
Thereafter		2,189
Total	$	5,877

Base lease payments under Fremont lease

Total base lease payments under the Fremont lease, including a fixed 3% management fee and 3% escalations, under the lease agreement for the years ending December 31, is shown below (in thousands):

Years Ending December 31,	Minimum lease payments
2016	$	1,271
2017		1,310
2018		1,347
2019		1,387
2020		1,430
Thereafter		2,604
Total	$	9,349

Future minimum operating lease payments

Remaining minimum annual lease payments under the various operating leases for the years ending after December 31, 2015 are as follows (in thousands):

Year Ending December 31,	Minimum lease payments
2016	$	2,070
2017		2,155
2018		2,186
2019		2,224
2020		2,292
Thereafter		4,792
Total	$	15,719

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Taxes [Abstract]

Components of Deferred Tax Assets and Liabilities

The primary components of the deferred tax assets and liabilities at December 31, 2015 and 2014 were as follows (in thousands):

Deferred tax assets/(liabilities):	2015			2014
Net operating loss carryforwards	$	78,268		$	58,693
Research & development and other credits		8,331			5,230
Patents and licenses		(6,860	)		(8,153	)
Equity method investment gain		(1,333	)		-
Stock options		670			1,561
Other, net		(263	)		(1	)
Total		78,813			57,329
Valuation allowance		(78,813	)		(61,844	)
Net deferred tax liabilities	$	-		$	(4,515	)

Income Tax Rate Reconciliation

Income taxes differed from the amounts computed by applying the U.S. federal income tax of 34% to pretax losses from operations as a result of the following:

	Year Ended December 31,
	2015			2014			2013
Computed tax benefit at federal statutory rate		34	%		34	%		34	%
Research & development and other credits		2	%		3	%		-
Permanent differences		(4	%)		(1	%)		(15	%)
Losses for which no benefit has been recognized		(34	%)		(24	%)		(18	%)
State tax benefit, net of effect on federal income taxes		10	%		3	%		4	%
Foreign rate differential		(1	%)		(1	%)		1	%
		7	%		14	%		6	%

Enterprise-wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2015

Enterprise wide Disclosures [Abstract]

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor. (In thousands)

	Revenues for the Year ending December 31,
Geographic Area	2015			2014			2013
Domestic		$	5,976		$	3,586		$	2,106
Asia			1,060			1,658			2,328
Total revenues		$	7,036		$	5,244		$	4,434

Sources of Revenues

	Revenues for the Year ending December 31,
Sources of Revenues	2015		2014		2013
Hospira		2.0%		3.0%		6.5%
CJ Health		0.3%		1.0%		1.7%
GE Health		4.8%		-%		-%
Summit⁽¹⁾		-%		-%		20.3%
CIRM		42.7%		19.7%		-%
NIH		6.5%		12.5%		5.0%
OCS		14.4%		31.3%		27.9%
Subscription and Advertising (various customers)		29.4%		32.5%		38.6%

(1)

BioTime recognized the unamortized balance of the Summit license fees during the fourth quarter of 2013 as a result of the termination of its license agreements with Summit.

Selected Quarterly Financial Information (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2015

Selected Quarterly Financial Information (UNAUDITED) [Abstract]

Selected Quarterly Financial Information

Year Ended December 31, 2015	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Revenues, net	$	1,000		$	1,749		$	1,874		$	1,306
Operating expenses		14,502			15,245			18,978			23,013
Loss from operations		(13,502	)		(13,496	)		(17,104	)		(21,707	)
Net loss attributable to BioTime, Inc.⁽¹⁾		(10,167	)		(9,691	)		(13,626	)		(13,507	)

Basic and diluted net loss per share	$	(0.13	)	$	(0.12	)	$	(0.18	)	$	(0.16	)

Year Ended December 31, 2014
Revenues, net	$	935		$	855		$	960		$	1,657
Operating expenses		12,073			13,917			13,098			16,001
Loss from operations		(11,138	)		(13,062	)		(12,138	)		(14,345	)
Net loss attributable to BioTime, Inc.⁽¹⁾		(8,099	)		(9,520	)		(8,268	)		(10,525	)

Basic and diluted net loss per share	$	(0.14	)	$	(0.16	)	$	(0.12	)	$	(0.14	)

(1)

Net of $4.5 million and $7.4 million of deferred income tax benefits for 2015 and 2014 respectively.

Organization, Basis of Presentation and Liquidity (Details) - USD ($)
$ in Thousands

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Noncontrolling Interest [Line Items]

Accumulated deficit

$ (229,181)

$ (182,190)

Shareholders' equity

76,447

$ 62,723

$ 42,262

$ 24,294

Parent [Member]

Noncontrolling Interest [Line Items]

Accumulated deficit

229,200

Working capital

34,800

Shareholders' equity

76,400

Cash, cash equivalents and available for sale securities

$ 43,000

Asterias Biotherapeutics, Inc. [Member] | USA [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

57.10%

Cell Cure Neurosciences, Ltd. [Member] | Israel [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

^[1]

62.50%

ES Cell International Pte., Ltd. [Member] | Singapore [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

100.00%

LifeMap Sciences, Inc. [Member] | USA [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

77.90%

LifeMap Sciences, Ltd. [Member] | Israel [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

^[2]

0.00%

LifeMap Solutions, Inc [Member] | USA [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

^[2]

0.00%

OncoCyte Corporation [Member] | USA [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

57.70%

OrthoCyte Corporation [Member] | USA [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

100.00%

ReCyte Therapeutics, Inc. [Member] | USA [Member]

Noncontrolling Interest [Line Items]

BioTime Ownership

94.80%

[1]	Includes shares owned by BioTime, Asterias and ESI.
[2]	LifeMap Sciences, Ltd. and LifeMap Solutions, Inc. are wholly-owned subsidiaries of LifeMap Sciences, Inc.

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]
Net trade receivable	$ 754,000	$ 549,000
Grants receivable	324,000	493,000
Allowance for doubtful accounts	$ 101,000
Ownership percentage	20.00%
Foreign currency translation and other comprehensive loss, foreign currency transaction gains and losses [Abstract]
Foreign currency gain (loss) included in comprehensive loss	$ (423,000)	122,900
Change in foreign currency translation and other comprehensive income/(loss) from equity investments	(424,000)	125,000	$ 119,000
Foreign currency transaction gain (loss) other than functional currency	$ 5,000	$ (338,000)
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years
Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	36 months
Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Equipment useful life	120 months
LifeMap Sciences, Ltd. [Member]
Available for sale securities in foreign investments [Abstract]
Common stock of HDST shares acquired	9,180,000
Common stock value of HDST shares acquired	$ 850,000
Value of available for sale securities	753,000
Unrealized loss included in other comprehensive loss	$ 100,000
Licensed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible asset, useful life	10 years
Treasury Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)	4,472,586	4,893,942	10,697,715
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)	5,194,313	3,974,326	4,567,135
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted loss per share (in shares)	9,190,782	9,194,679	9,751,615

Inventory, net (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory, net [Abstract]
Inventory of raw material and finished goods products on-site	$ 1,000	$ 266,000
Inventory held by third party on consignment		$ 12,800

Equipment, net and construction in progress (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equipment, furniture and fixtures, and construction in progress [Abstract]
Equipment, net and construction in progress	$ 7,539,000	$ 2,858,000
Equipment, furniture, and fixtures included in capital lease borrowings	33,800	115,000
Depreciation expense	1,078,000	1,051,000	$ 657,000
Reimbursement from landlord on construction in progress	3,789,000	0	$ 0
Furniture and Fixtures, and Construction in Progress [Member]
Equipment, furniture and fixtures, and construction in progress [Abstract]
Equipment, furniture and fixtures	10,757,000	4,871,000
Construction in progress	93,000	406,000
Accumulated depreciation	(3,311,000)	(2,419,000)
Equipment, net and construction in progress	7,539,000	$ 2,858,000
Construction in Progress [Member]
Equipment, furniture and fixtures, and construction in progress [Abstract]
Tenant improvement allowance under lease agreement	4,400,000
Reimbursement from landlord on construction in progress	3,800,000
Amount remaining under lease agreement	$ 600,000

Intangible assets, net (Details) - USD ($)	12 Months Ended
Intangible assets, net (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Intangible assets, net [Abstract]
Intangible assets	$ 52,563,000	$ 52,562,000
Accumulated amortization	(18,971,000)	(13,714,000)
Intangible assets, net	$ 33,592,000	38,848,000
Intangible assets, useful life	10 years
Amortization of intangible assets	$ 5,256,000	7,360,000	$ 3,296,000
Adjustments to intangible assets due to deferred tax liability		2,200,000
Accumulated amortization of intangible assets		270,000
Amortization expense for intangible assets		1,900,000
Intangible assets future amortization expense [Abstract]
2016	5,256,000
2017	5,256,000
2018	5,256,000
2019	5,256,000
2020	4,480,000
Thereafter	8,088,000
Intangible assets, net	$ 33,592,000	$ 38,848,000

Royalty Obligation and Deferred License Fees (Details)	12 Months Ended
Royalty Obligation and Deferred License Fees (Details)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 ILS (₪)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	10 years	10 years
Amortization of deferred license, royalty and subscription revenues	$ 102,000		$ (1,000)	$ (915,000)
Amortization of deferred license fees [Abstract]
2016	148,000
2017	130,000
2018	84,000
2019	34,000
2020	13,000
Thereafter	61,000
Total	470,000
Prepaid expenses in other current assets	148,000
Deferred license fees in noncurrent assts	322,000		337,000
WARF [Member]
Finite-Lived Intangible Assets [Line Items]
Licensing fees paid	295,000
Amortization of deferred license, royalty and subscription revenues	$ 210,100		151,000
WARF [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	2.00%	2.00%
WARF [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	4.00%	4.00%
Ocata Therapeutics, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years	20 years
Royalty rate on sale of products and services	8.00%	8.00%
Licensing fees paid	$ 250,000
Amortization of deferred license, royalty and subscription revenues	209,900		$ 184,900
Maximum royalty payments	$ 1,000,000
Hadasit [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	5.00%	5.00%
Payment for patent expense	$ 63,900	₪ 249,100
Minimum percentage for underlying net sales	1.20%	1.20%
Annual minimum royalty due	$ 100,000
Minimum amount of sublicensing receipts	$ 50,000,000
Hadasit [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Fees for sublicense	10.00%	10.00%
Hadasit [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Fees for sublicense	30.00%	30.00%
Hadasit (Clinical trial phase I) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 250,000
Hadasit (Clinical trial phase II) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	250,000
Hadasit (Clinical trial phase III) [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 1,000,000
University of Utah License [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	3.00%	3.00%
Fees for sublicense	30.00%	30.00%
Payments for attaining milestone	$ 5,000
Number of licensed patents issued that trigger payments to licensor \| shares	5
Minimum royalty amount in 2015	$ 2,500
Minimum royalty amount in 2016 and thereafter	30,000
University of Utah License [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 2,500
Number of other licensees that triggers reduction in payments for attaining milestone \| shares	2
University of Utah License, Milestone I [Member]
Finite-Lived Intangible Assets [Line Items]
Payments for attaining milestone	$ 225,000
Asterias License from the University of California [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	1.00%	1.00%
Fees for sublicense	7.50%	7.50%
Annual minimum royalty due	$ 5,000
Maximum reduction in royalty payments	50.00%
Period of notice for termination of the agreement	60 days	60 days
Asterias Sublicenes from Geron [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty rate on sale of products and services	1.00%	1.00%
Licensing fees paid	$ 65,000
Period of notice for termination of the agreement	90 days	90 days
Annual license maintenance fee	$ 10,000
OrthoCyte Agreements with Heraeus [Member]
Finite-Lived Intangible Assets [Line Items]
Period of notice for termination of the agreement	90 days	90 days
Amortization of deferred license fees [Abstract]
Up-front payment	$ 1,000,000
Expected life of agreement	3 years 3 months	3 years 3 months
Recognized revenue	$ 77,000
Maximum period to milestone payments become due	14 days	14 days
Uncured agreement period	60 days	60 days

Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable	$ 2,798	$ 2,297
Accrued expenses	5,021	3,125
Accrued bonuses	1,126	964
Other current liabilities	432	417
Total	$ 9,377	$ 6,803

Related Party Transactions (Details)			1 Months Ended							12 Months Ended
Related Party Transactions (Details)	May. 31, 2015 USD ($) Investor shares	Oct. 31, 2014 $ / shares shares	Nov. 30, 2015 USD ($)	Oct. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2015 USD ($) $ / shares shares	Apr. 30, 2015 USD ($) Investor $ / shares	Feb. 28, 2015 USD ($) $ / shares shares	Jun. 30, 2014 USD ($) Investor shares	Dec. 31, 2015 USD ($) ft² shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($)
Related Party Transaction [Line Items]
Rent per month										$ 5,050
Area of office space (in square feet) \| ft²										900
Proceeds from issuance of common shares										$ 34,123,000	$ 44,150,000	$ 25,939,000
Principal and accumulated interest										$ 255,000	$ 471,000	0
Common shares, issued (in shares) \| shares										94,894,140	83,121,698
Non-cash stock-based compensation										$ 11,050,000	$ 4,455,000	$ 3,218,000
BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares				$ 5,100,000	$ 8,600,000
Number of shares sold (in shares) \| shares		9,431,398		1,600,000	2,607,401				5,000,000	175,000	5,545,160
Stock price (in dollars per share) \| $ / shares		$ 3.12		$ 3.19	$ 3.29
Number of investors \| Investor									2
George Karfunkel [Member] \| BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares) \| shares									4,000,000
George Karfunkel [Member] \| Asterias Warrants [Member]
Related Party Transaction [Line Items]
Number of shares purchased (in shares) \| shares									4,000,000
Broadwood Partners LP [Member] \| BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares) \| shares									1,000,000
Number of shares purchased (in shares) \| shares					2,431,611
Former Executive [Member]
Related Party Transaction [Line Items]
Payments of severance compensation			$ 267,000
Non-cash stock-based compensation			1,800,000
Asterias Biotherapeutics [Member]
Related Party Transaction [Line Items]
Number of shares purchased (in shares) \| shares									5,000,000
Asterias Biotherapeutics [Member] \| BioTime Common Stock [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares									$ 12,500,000
Number of shares sold (in shares) \| shares									5,000,000
Number of investors \| Investor									2
Asterias Biotherapeutics [Member] \| Asterias Warrants [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares									$ 11,700,000
Number of shares purchased (in shares) \| shares									1,000,000
Asterias Biotherapeutics [Member] \| Series A Common Stock [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares								$ 5,500,000
Number of shares sold (in shares) \| shares								1,410,255
Stock price (in dollars per share) \| $ / shares								$ 3.90
Number of shares purchased (in shares) \| shares								1,025,640
Cell Cure Neurosciences, Ltd. [Member]
Related Party Transaction [Line Items]
Number of investors \| Investor							2
Stated interest rate							3.00%
Conversion price (in dollars per share) \| $ / shares							$ 20.00
Estimated fair market value (in dollars per share) \| $ / shares							$ 41.00
Principal and accumulated interest							$ 471,000
Accrued interest is payable period							3 years
Effective annual interest rate							23.00%
Carrying value of convertible notes										$ 324,000
Amount of convertible note										748,000
Unamortized debt discount										$ 424,000
Cell Cure Neurosciences, Ltd. [Member] \| Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Principal and accumulated interest			$ 66,000				$ 188,000
Unamortized debt discount							$ 659,000
OncoCyte [Member] \| Subscription Agreements [Member]
Related Party Transaction [Line Items]
Number of investors \| Investor	2
OncoCyte [Member] \| Second Agreement [Member]
Related Party Transaction [Line Items]
Non-compete Agreement Term						1 year
Fair value of warrants						$ 65,400
OncoCyte [Member] \| Second Agreement [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Investor passive ownership threshold						5.00%
OncoCyte [Member] \| Investors [Member] \| OncoCyte Common Stock [Member] \| Subscription Agreements [Member]
Related Party Transaction [Line Items]
Proceeds from issuance of common shares	$ 3,300,000
Common shares, issued (in shares) \| shares	3,000,000
OncoCyte [Member] \| Investors [Member] \| OncoCyte Common Stock [Member] \| Second Agreement [Member]
Related Party Transaction [Line Items]
Pre-offer valuation of rights						$ 40,000,000
Maximum purchase price of shares of pre-offer						$ 3,000,000
Number of shares that can be called by warrants (in shares) \| shares						3,000,000
Warrants exercise price (in dollars per share) \| $ / shares						$ 0.01
OncoCyte [Member] \| George Karfunkel [Member] \| OncoCyte Common Stock [Member] \| Subscription Agreements [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares) \| shares	1,000,000
OncoCyte [Member] \| George Karfunkel [Member] \| OncoCyte Common Stock [Member] \| Subscription Agreements [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Ownership interest rate	5.00%

Shareholders' Equity, Warrants and Options (Details) - Warrants [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Numbers of Warrants [Roll Forward]
Warrants Outstanding Beginning Balance (in shares)	9,195	9,752
Exercised (in shares)	(4)	(557)
Warrants Outstanding Ending Balance (in shares)	9,191	9,195
Per share exercise price [Abstract]
Outstanding Beginning Balance (in dollars per share)	$ 5.00
Exercised (in dollars per share)	5.00	$ 10.00
Outstanding Ending Balance (in dollars per share)	5.00	5.00
Weighted Average Exercise Price [Abstract]
Outstanding Beginning Balance (in dollars per share)	5.00	5.29
Exercised (in dollars per share)	5.00	10.00
Outstanding Ending Balance(in dollars per share)	$ 5.00	$ 5.00
Weighted average remaining contractual life	2 years 6 months 14 days	3 years 5 months 1 day
Minimum [Member]
Per share exercise price [Abstract]
Outstanding Beginning Balance (in dollars per share)		$ 5.00
Maximum [Member]
Per share exercise price [Abstract]
Outstanding Beginning Balance (in dollars per share)		$ 10.00

Shareholders' Equity, Preferred and Common Shares (Details)		1 Months Ended			12 Months Ended
	Oct. 31, 2014 USD ($) $ / shares shares	Oct. 31, 2015 USD ($) Investor $ / shares shares	Sep. 30, 2015 USD ($) Shareholder $ / shares shares	Jun. 30, 2014 USD ($) Investor shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares
Preferred Shares [Abstract]
Preferred shares, shares authorized (in shares)					2,000,000	2,000,000
Preferred shares, issued and outstanding (in shares)					0	70,000
Promissory notes \| $					$ 363,000
Number of common stock issued for exchange of each common stock held of other company as per option agreement (in shares)					1
Common Shares [Abstract]
Common shares, authorized (in shares)					125,000,000	125,000,000
Common shares, par value (in dollars per share) \| $ / shares					$ 0	$ 0
Common shares, issued (in shares)					94,894,140	83,121,698
Common shares, outstanding (in shares)					90,421,554	78,227,756
Treasury stock (in shares)					4,472,586	4,893,942
Equity ownership percentage					20.00%
OncoCyte Corporation [Member]
Common Shares [Abstract]
Shares distributed to shareholders (in shares)					4,700,000
Shares conversion ratio					20
Reduction in equity method investment \| $					$ 712,000
Equity ownership percentage					57.80%	76.50%
Taxable gain \| $					$ 7,400,000
Decrease in equity method investment					18.70%
Series A Preferred Stock [Member]
Preferred Shares [Abstract]
Preferred shares, issued and outstanding (in shares)					70,000
Cummulative preferred dividend, percent					3.00%
Conversion price (in dollars per share) \| $ / shares					$ 4.00
Conversion ratio					12.5
BioTime Common Stock [Member]
Common Shares [Abstract]
Number of shares sold (in shares)	9,431,398	1,600,000	2,607,401	5,000,000	175,000	5,545,160
Proceeds from sale of shares \| $	$ 29,400,000	$ 5,100,000	$ 8,600,000	$ 12,500,000	$ 615,000	$ 17,400,000
Number of investors \| Investor				2
Number of shareholders \| Shareholder			3
Price per share (in dollars per share) \| $ / shares	$ 3.12	$ 3.19	$ 3.29
BioTime Common Stock [Member] \| Asterias Biotherapeutics [Member]
Common Shares [Abstract]
Number of shares sold (in shares)				5,000,000
Proceeds from sale of shares \| $				$ 12,500,000
Number of shares purchased (in shares)				5,000,000
Number of investors \| Investor				2
BioTime Common Stock [Member] \| OncoCyte Corporation [Member]
Common Shares [Abstract]
Number of shares sold (in shares)		246,356
Proceeds from sale of shares \| $		$ 771,094
Number of investors \| Investor		1
Price per share (in dollars per share) \| $ / shares		$ 3.13
BioTime Common Stock [Member] \| Certain investors [Member]
Common Shares [Abstract]
Number of shares sold (in shares)		6,530,612
Proceeds from sale of shares \| $		$ 20,400,000
Price per share (in dollars per share) \| $ / shares		$ 3.13

Stock Option Plans (Details) - USD ($)	12 Months Ended
Stock Option Plans (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period when options may not be granted or exercised	10 years
Weighted-average estimated fair value of stock options granted (in dollars per share)	$ 0	$ 0
Stock-based compensation expense	$ 11,061,000	$ 4,456,000	$ 3,045,000
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 173,100
0.003-$0.75 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	$ 0.003
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 0.75
Number Outstanding (in shares)	5,256,226
Options Outstanding, Weighted Avg. Remaining Contractual Life	4 years 11 months 16 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.36
Number Exercisable (in shares)	5,091,506
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0.37
1.00-1.75 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	1.00
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 1.75
Number Outstanding (in shares)	1,986,772
Options Outstanding, Weighted Avg. Remaining Contractual Life	4 years 10 months 13 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 1.58
Number Exercisable (in shares)	1,157,886
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 1.50
2.05-2.34 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	2.05
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 2.34
Number Outstanding (in shares)	4,361,666
Options Outstanding, Weighted Avg. Remaining Contractual Life	5 years 6 months 11 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.26
Number Exercisable (in shares)	2,066,146
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 2.18
3.88-6.25 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	3.88
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 6.25
Number Outstanding (in shares)	75,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	1 month 13 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.105
Number Exercisable (in shares)	2,708
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0.01
27.00-42.02 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	27.00
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 42.02
Number Outstanding (in shares)	7,840
Options Outstanding, Weighted Avg. Remaining Contractual Life	5 years 9 months 18 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 37.35
Number Exercisable (in shares)	7,840
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 37.35
500.00 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 500.00
Number Outstanding (in shares)	13,167
Options Outstanding, Weighted Avg. Remaining Contractual Life	14 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.31
Number Exercisable (in shares)	1,993
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 0.86
0.003-$500.00 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	0.003
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 500.00
Number Outstanding (in shares)	11,700,671
Options Outstanding, Weighted Avg. Remaining Contractual Life	5 years 2 months 1 day
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 1.90
Number Exercisable (in shares)	8,328,079
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 1.13
2002 Plan and 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs	$ 10.1
Weighted average recognition period	6 years 8 months 23 days
Weighted-average estimated fair value of stock options granted (in dollars per share)	$ 3.72	$ 3.43
Weighted-average assumptions [Abstract]
Expected life	5 years 7 months 13 days	6 years 8 months 1 day
Risk-free interest rates	1.70%	2.19%
Volatility	65.82%	83.20%
Dividend yield	0.00%	0.00%
Options and Restricted Stock Available for Grant [Roll Forward]
Increase in option pool (in shares)	6,000,000
Options exercised (in shares)	0	0
Number of Options and Restricted Stock Outstanding [Roll Forward]
Increase in option pool (in shares)	0
Options exercised (in shares)	(156,000)	(2,060,000)
Weighted Average Exercise Price [Roll Forward]
Increase in option pool (in dollars per share)	$ 0
Options exercised (in dollars per share)	$ 4.00	$ 0.58
Options Available for Grant [Rollforward]
Beginning of the period (in shares)	668,000	2,315,000
Increase option pool (in shares)	6,000,000
Exercised (in shares)	0	0
End of the period (in shares)	5,257,000	668,000	2,315,000
Number of Options Outstanding [Rollforward]
Outstanding, beginning of the period (in shares)	3,974,000	4,567,000
Increase option pool (in shares)	0
Exercised (in shares)	(156,000)	(2,060,000)
Outstanding, end of the period (in shares)	5,194,000	3,974,000	4,567,000
Weighted Average Exercise Price [Rollforward]
Outstanding, beginning of the period (in dollars per share)	$ 4.04	$ 2.71
Increase option pool (in dollars per share)	0
Exercised (in dollars per share)	4.00	0.58
Outstanding end of the period (in dollars per share)	3.93	$ 4.04	$ 2.71
2002 Plan and 2012 Plan [Member] \| 2.52-3.96 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	2.52
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 3.96
Number Outstanding (in shares)	3,196,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	7 years 29 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.53
Number Exercisable (in shares)	1,165,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 3.47
2002 Plan and 2012 Plan [Member] \| 4.02-4.95 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	4.02
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 4.95
Number Outstanding (in shares)	1,628,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	5 years 3 months 18 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 4.33
Number Exercisable (in shares)	962,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.26
2002 Plan and 2012 Plan [Member] \| 5.02-8.58 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	5.02
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 8.58
Number Outstanding (in shares)	370,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	1 year 1 month 17 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 6.12
Number Exercisable (in shares)	361,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 6.15
2002 Plan and 2012 Plan [Member] \| $2.52-$8.58 [Member]
Additional Information regarding options outstanding [Abstract]
Range of Exercise Prices, Lower Range Limit (in dollars per share)	2.52
Range of Exercise Prices, Upper Range Limit (in dollars per share)	$ 8.58
Number Outstanding (in shares)	5,194,000
Options Outstanding, Weighted Avg. Remaining Contractual Life	6 years 1 month 6 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 3.93
Number Exercisable (in shares)	2,488,000
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 4.16
2002 Plan [Member]
Options and Restricted Stock Available for Grant [Roll Forward]
Options expired/forfeited/cancelled (in shares)	0	0
Number of Options and Restricted Stock Outstanding [Roll Forward]
Options forfeited/cancelled/expired (in shares)	(35,000)	(179,000)
Weighted Average Exercise Price [Roll Forward]
Options forfeited/cancelled/expired (in dollars per share)	$ 6.72	$ 4.32
Options Available for Grant [Rollforward]
Forfeited/cancelled/expired (in shares)	0	0
Number of Options Outstanding [Rollforward]
Forfeited/cancelled/expired (in shares)	(35,000)	(179,000)
Weighted Average Exercise Price [Rollforward]
Forfeited/cancelled/expired (in dollars per share)	$ 6.72	$ 4.32
2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for future issuance (in shares)			10,000,000
Period when options may not be granted or exercised			10 years
Options and Restricted Stock Available for Grant [Roll Forward]
Options granted (in shares)	(1,650,000)	(2,170,000)
Options expired/forfeited/cancelled (in shares)	239,000	523,000
Number of Options and Restricted Stock Outstanding [Roll Forward]
Options granted (in shares)	1,650,000	2,170,000
Options forfeited/cancelled/expired (in shares)	(239,000)	(524,000)
Weighted Average Exercise Price [Roll Forward]
Options granted (in dollars per share)	$ 3.72	$ 3.54
Options forfeited/cancelled/expired (in dollars per share)	$ 3.82	$ 3.72
Options Available for Grant [Rollforward]
Granted (in shares)	(1,650,000)	(2,170,000)
Forfeited/cancelled/expired (in shares)	239,000	523,000
Number of Options Outstanding [Rollforward]
Granted (in shares)	1,650,000	2,170,000
Forfeited/cancelled/expired (in shares)	(239,000)	(524,000)
Weighted Average Exercise Price [Rollforward]
Granted (in dollars per share)	$ 3.72	$ 3.54
Forfeited/cancelled/expired (in dollars per share)	$ 3.82	$ 3.72
OncoCyte, OrthoCyte and ReCyte Therapeutics Stock Option Plans [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	4,000,000
BioTime Asia Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options to purchase for employees (in shares)	4,500,000
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	1,600
OncoCyte Common Stock Option Plans [Member]
Options and Restricted Stock Available for Grant [Roll Forward]
Increase in option pool (in shares)	4,000,000
Options granted (in shares)	(2,875,000)
Options exercised (in shares)	0
Options expired/forfeited/cancelled (in shares)	1,121,000	28,000
Number of Options and Restricted Stock Outstanding [Roll Forward]
Increase in option pool (in shares)	0
Options granted (in shares)	2,875,000
Options exercised (in shares)	(6,000)
Options forfeited/cancelled/expired (in shares)	(1,121,000)	(28,000)
Weighted Average Exercise Price [Roll Forward]
Increase in option pool (in dollars per share)	$ 0
Options granted (in dollars per share)	1.10
Options exercised (in dollars per share)	0.67
Options forfeited/cancelled/expired (in dollars per share)	$ 0.79	$ 1.00
Options Available for Grant [Rollforward]
Beginning of the period (in shares)	1,278,000	1,250,000
Increase option pool (in shares)	4,000,000
2 for 1 reverse stock split (in shares)	(1,762,000)
Granted (in shares)	(2,875,000)
Exercised (in shares)	0
Forfeited/cancelled/expired (in shares)	1,121,000	28,000
Options granted after reverse stock split (in shares)	(10,000)
Options forfeited/cancelled after reverse stock split (in shares)	5,000
End of the period (in shares)	1,757,000	1,278,000	1,250,000
Number of Options Outstanding [Rollforward]
Outstanding, beginning of the period (in shares)	2,722,000	2,750,000
Increase option pool (in shares)	0
2 for 1 reverse stock split (in shares)	(2,235,000)
Granted (in shares)	2,875,000
Exercised (in shares)	(6,000)
Forfeited/cancelled/expired (in shares)	(1,121,000)	(28,000)
Options granted after reverse stock split (in shares)	10,000
Options forfeited/cancelled after reverse stock split (in shares)	(5,000)
Outstanding, end of the period (in shares)	2,240,000	2,722,000	2,750,000
Weighted Average Exercise Price [Rollforward]
Outstanding, beginning of the period (in dollars per share)	$ 0.76	$ 0.76
Increase option pool (in dollars per share)	0
2 for 1 reverse stock split (in dollars per shares)	2.02
Granted (in dollars per share)	1.10
Exercised (in dollars per share)	0.67
Forfeited/cancelled/expired (in dollars per share)	0.79	1.00
Options granted after reverse stock split (in dollars per share)	3.60
Options forfeited/cancelled after reverse stock split (in dollars per share)	2.00
Outstanding end of the period (in dollars per share)	$ 3	$ 0.76	$ 0.76
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	2,000,000
Cell Cure Neurosciences' Option Plan [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	14,100
Lifemap Stock Option Plan [Member]
Additional Information regarding options outstanding [Abstract]
Authorize number of shares under stock option plan (in shares)	8,000,000	18,667
Asterias Equity Incentive Plan [Member]
Options and Restricted Stock Available for Grant [Roll Forward]
Beginning of the period (in shares)	950,000	1,660,000
Increase in option pool (in shares)	3,500,000
Options granted (in shares)	(2,005,000)	(1,590,000)
Options exercised (in shares)	0
Options expired/forfeited/cancelled (in shares)	9,000	1,280,000
Restricted stock issued (in shares)	(388,000)	(400,000)
Restricted stock forfeited (in shares)	1,000
End of the period (in shares)	2,067,000	950,000	1,660,000
Number of Options and Restricted Stock Outstanding [Roll Forward]
Outstanding, beginning of the period (in shares)	3,347,000	2,840,000
Increase in option pool (in shares)	0
Options granted (in shares)	2,005,000	1,590,000
Options exercised (in shares)	(13,000)	(3,000)
Options forfeited/cancelled/expired (in shares)	(9,000)	(1,280,000)
Restricted stock vested (in shares)	(145,000)
Restricted stock issued (in shares)	194,000	200,000
Restricted stock forfeited (in shares)	(1,000)
Outstanding, end of the period (in shares)	5,178,000	3,347,000	2,840,000
Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of the period (in dollars per share)	$ 2.42	$ 2.34
Increase in option pool (in dollars per share)	0
Options granted (in dollars per share)	3.81	2.50
Options exercised (in dollars per share)	2.34	2.34
Options forfeited/cancelled/expired (in dollars per share)	3.22	2.34
Restricted stock vested (in dollars per share)	3.90
Restricted stock issued (in dollars per share)	3.90	2.34
Restricted stock forfeited (in dollars per share)	3.90
Outstanding end of the period (in dollars per share)	$ 2.94	$ 2.42	$ 2.34
Options Available for Grant [Rollforward]
Increase option pool (in shares)	3,500,000
Granted (in shares)	(2,005,000)	(1,590,000)
Exercised (in shares)	0
Forfeited/cancelled/expired (in shares)	9,000	1,280,000
Number of Options Outstanding [Rollforward]
Increase option pool (in shares)	0
Granted (in shares)	2,005,000	1,590,000
Exercised (in shares)	(13,000)	(3,000)
Forfeited/cancelled/expired (in shares)	(9,000)	(1,280,000)
Weighted Average Exercise Price [Rollforward]
Increase option pool (in dollars per share)	$ 0
Granted (in dollars per share)	3.81	$ 2.50
Exercised (in dollars per share)	2.34	2.34
Forfeited/cancelled/expired (in dollars per share)	$ 3.22	$ 2.34
Asterias Equity Incentive Plan [Member] \| Restricted Stock [Member]
Number of Options and Restricted Stock Outstanding [Roll Forward]
Restricted stock vested (in shares)	(200,000)
Weighted Average Exercise Price [Roll Forward]
Restricted stock vested (in dollars per share)	$ 2.34

Stock Option Plans, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
All stock-based compensation expense [Abstract]
All stock-based compensation expense included in expenses	$ 11,061	$ 4,456	$ 3,045
Research and Development [Member]
All stock-based compensation expense [Abstract]
All stock-based compensation expense included in expenses	3,267	1,310	830
General and Administrative [Member]
All stock-based compensation expense [Abstract]
All stock-based compensation expense included in expenses	$ 7,794	$ 3,146	$ 2,215

Stock Option Plans, Subsidiaries' Stock Options Plans (Details) - $ / shares
shares in Thousands

12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

OrthoCyte Corporation [Member]

Options Available for Grant [Rollforward]

Beginning of the period (in shares)

^[1]

1,355

Forfeited/cancelled/expired (in shares)

End of the period (in shares)

^[1]

1,371

1,355

Number of Options Outstanding [Rollforward]

Outstanding, beginning of the period (in shares)

^[1]

2,645

Forfeited/cancelled/expired (in shares)

(16)

Outstanding, end of the period (in shares)

^[1]

2,629

2,645

Weighted Average Exercise Price [Rollforward]

Outstanding, beginning of the period (in dollars per share)

^[1]

$ 0.08

Forfeited/cancelled/expired (in dollars per share)

0.07

Outstanding end of the period (in dollars per share)

^[1]

$ 0.08

ReCyte Therapeutics, Inc. [Member]

Options Available for Grant [Rollforward]

Beginning of the period (in shares)

^[1]

2,710

Forfeited/cancelled/expired (in shares)

End of the period (in shares)

2,721

2,710

^[1]

Number of Options Outstanding [Rollforward]

Outstanding, beginning of the period (in shares)

^[1]

1,290

Forfeited/cancelled/expired (in shares)

(11)

Outstanding, end of the period (in shares)

1,279

1,290

^[1]

Weighted Average Exercise Price [Rollforward]

Outstanding, beginning of the period (in dollars per share)

^[1]

$ 2.05

Forfeited/cancelled/expired (in dollars per share)

2.05

Outstanding end of the period (in dollars per share)

$ 2.05

^[1]

LifeMap Sciences, Inc. [Member]

Options Available for Grant [Rollforward]

Beginning of the period (in shares)

471

413

Granted (in shares)

(131)

Forfeited/cancelled/expired (in shares)

207

End of the period (in shares)

547

471

Number of Options Outstanding [Rollforward]

Outstanding, beginning of the period (in shares)

1,871

1,929

Granted (in shares)

131

Forfeited/cancelled/expired (in shares)

(207)

(58)

Outstanding, end of the period (in shares)

1,795

1,871

Weighted Average Exercise Price [Rollforward]

Outstanding, beginning of the period (in dollars per share)

$ 1.48

$ 1.49

Granted (in dollars per share)

1.92

Forfeited/cancelled/expired (in dollars per share)

1.79

1.48

Outstanding end of the period (in dollars per share)

$ 1.47

$ 1.48

LifeMap Solutions, Inc [Member]

Options Available for Grant [Rollforward]

Option pool added upon incorporation (in shares)

Beginning of the period (in shares)

Granted (in shares)

(2)

(13)

Forfeited/cancelled/expired (in shares)

End of the period (in shares)

Number of Options Outstanding [Rollforward]

Outstanding, beginning of the period (in shares)

Granted (in shares)

Forfeited/cancelled/expired (in shares)

(1)

Outstanding, end of the period (in shares)

Weighted Average Exercise Price [Rollforward]

Outstanding, beginning of the period (in dollars per share)

$ 500.00

Granted (in dollars per share)

500.00

$ 500.00

Forfeited/cancelled/expired (in dollars per share)

500.00

Outstanding end of the period (in dollars per share)

$ 500.00

BioTime Asia, Limited [Member]

Options Available for Grant [Rollforward]

Stock option available for future grants (in shares)

1,300

Number of Options Outstanding [Rollforward]

Outstanding, end of the period (in shares)

300

Weighted Average Exercise Price [Rollforward]

Outstanding end of the period (in dollars per share)

$ 0.01

Cell Cure Neurosciences, Ltd. [Member]

Options Available for Grant [Rollforward]

Stock option available for future grants (in shares)

1,860

Number of Options Outstanding [Rollforward]

Outstanding, end of the period (in shares)

12,240

Weighted Average Exercise Price [Rollforward]

Outstanding end of the period (in dollars per share)

$ 23.93

[1]	There was no grant activity during 2014.

Sales of BioTime Common Shares by Subsidiaries (Details) - BioTime Common Stock [Member]		1 Months Ended			12 Months Ended
	Oct. 31, 2014 USD ($) shares	Oct. 31, 2015 USD ($) Investor shares	Sep. 30, 2015 USD ($) shares	Jun. 30, 2014 USD ($) Investor shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($) shares
Related Party Transaction [Line Items]
Number of shares sold (in shares) \| shares	9,431,398	1,600,000	2,607,401	5,000,000	175,000	5,545,160
Number of investors \| Investor				2
Proceeds from sale of BioTime stock \| $	$ 29,400,000	$ 5,100,000	$ 8,600,000	$ 12,500,000	$ 615,000	$ 17,400,000
Asterias Biotherapeutics [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares) \| shares				5,000,000
Number of investors \| Investor				2
Proceeds from sale of BioTime stock \| $				$ 12,500,000
BioTime Subsidiaries [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares) \| shares			175,000
Proceeds from sale of BioTime stock \| $			$ 576,000
OncoCyte Corporation [Member]
Related Party Transaction [Line Items]
Number of shares sold (in shares) \| shares		246,356
Number of investors \| Investor		1
Proceeds from sale of BioTime stock \| $		$ 771,094

Investment in Common Stock of Ascendance Biotechnology, Inc. (Details) - USD ($) $ in Thousands		12 Months Ended
	Dec. 09, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Gain on acquisition		$ 3,694	$ 0	$ 0
Ascendance Biotechnology, Inc [Member]
Business Acquisition [Line Items]
Acquired equity interest	51.20%
Fair value of investment	$ 4,700
Carrying amount of assets	1,000
Gain on acquisition	$ 3,700

Commitments and Contingencies (Details)	12 Months Ended
Commitments and Contingencies (Details)	Dec. 31, 2015 USD ($) ft² m² Building Extension	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2015 ILS (₪) ft² m²	Dec. 31, 2015 HKD ft² m²
Operating Leased Assets [Line Items]
Rent expenses	$ 2,100,000	$ 2,000,000	$ 1,600,000
Portion of construction costs reimbursable by landlord	567,000	378,000
Deferred rent balance	158,000	$ 97,000
Alameda Operating Leases Future Minimum Payments Due Fiscal Year Maturity [Abstract]
2016	388,000
2017	789,000
2018	813,000
2019	837,000
2020	861,000
Thereafter	2,189,000
Total	5,877,000
Minimum annual lease payments under the Fremont operating lease [Abstract]
2016	1,271,000
2017	1,310,000
2018	1,347,000
2019	1,387,000
2020	1,430,000
Thereafter	2,604,000
Total	9,349,000
Minimum annual lease payments under the various operating leases [Abstract]
2016	2,070,000
2017	2,155,000
2018	2,186,000
2019	2,224,000
2020	2,292,000
Thereafter	4,792,000
Total	$ 15,719,000
New Alameda Lease [Member]
Operating Leased Assets [Line Items]
Lease term	7 years
Number of years lease can be extended	5 years
Leased area \| ft²	30,795			30,795	30,795
Number of buildings for lease \| Building	2
Tenant improvement allowance	$ 1,400,000
Additional tenant improvement allowance	$ 308,000
Interest on Additional Tenant Improvement Allowance	10.00%
Security Deposit	$ 846,862
Security deposit reduction in value after first twenty four months of lease term	423,431
Security deposit reduction in value after first thirty six months of lease term	346,135
Construction costs incurred for tenant improvements	93,000
Portion of construction costs reimbursable by landlord	0
Reporting Entities [Member] \| Office space in New York City [Member]
Operating Leased Assets [Line Items]
Base rent	$ 5,050
Asterias Biotherapeutics, Inc. [Member] \| Office space in New York City [Member]
Operating Leased Assets [Line Items]
Lease commencement date	Jul. 01, 2014
Lease term	1 year
Leased area \| ft²	120			120	120
Base rent	$ 3,512
Asterias Biotherapeutics, Inc. [Member] \| Office and research facility in Fremont [Member]
Operating Leased Assets [Line Items]
Lease commencement date	Oct. 01, 2014
Lease term	96 months
Number of years lease can be extended	5 years
Leased area \| ft²	44,000			44,000	44,000
Leased area during first 15 months (in square feet) \| ft²	22,000			22,000	22,000
Base rent	$ 50,985
Base rent increase rate	3.00%			3.00%	3.00%
Rent expenses	$ 1,300,000
Real estate taxes during first 15 months	50.00%			50.00%	50.00%
Tenant improvement allowance	$ 4,400,000
Planned investment in tenant improvements	5,500,000
Security Deposit	$ 300,000
Number of five year options to extend lease term \| Extension	2
Notice required to exercise five year option	1 year
Base rent effective January 1, 2016	$ 105,142
Percentage of base rent applied to management fees	3.00%
Percentage of base rent applied to escalations	3.00%
Construction costs incurred for tenant improvements	$ 4,900,000
Portion of construction costs reimbursable by landlord	4,400,000
Deferred rent balance	$ 178,700
LifeMap Sciences, Inc. [Member] \| Office space in Tel Aviv, Israel [Member]
Operating Leased Assets [Line Items]
Lease Expiration Date	Jun. 19, 2016
Leased area \| m²	104			104	104
Base rent	$ 1,800			₪ 7,280
LifeMap Sciences, Inc. [Member] \| Office space in Hong Kong [Member]
Operating Leased Assets [Line Items]
Lease commencement date	Dec. 01, 2015
Lease Expiration Date	May 31, 2016
Leased area \| m²	120			120	120
Base rent	$ 1,500				HKD 12,500
LifeMap Sciences, Inc. [Member] \| Office space in Marshfield, Massachusetts [Member]
Operating Leased Assets [Line Items]
Lease Expiration Date	Sep. 30, 2018
Leased area \| ft²	750			750	750
Base rent	$ 1,217
LifeMap Sciences, Inc. [Member] \| Office space in Hoboken, New Jersey [Member]
Operating Leased Assets [Line Items]
Lease Expiration Date	Feb. 28, 2018
Leased area \| ft²	200			200	200
Base rent	$ 1,150
LifeMap Sciences, Inc. [Member] \| Office space in San Jose, California [Member]
Operating Leased Assets [Line Items]
Lease Expiration Date	May 31, 2016
Leased area \| ft²	386			386	386
Base rent	$ 5,458
Cell Cure Neurosciences, Ltd. [Member] \| Office and laboratory space, Jerusalem, Israel [Member]
Operating Leased Assets [Line Items]
Lease Expiration Date	Nov. 30, 2016
Leased area \| m²	290			290	290
Base rent	$ 5,600			₪ 21,930
Liable for improvement cost	$ 9,000			₪ 36,000
Number of years, improvement cost spread	2 years 6 months

Income Taxes (Details) - USD ($)	1 Months Ended	12 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets/(liabilities) [Abstract]
Net operating loss carryforwards		$ 78,268,000	$ 58,693,000
Research & development and other credits		8,331,000	5,230,000
Patents and licenses		(6,860,000)	(8,153,000)
Equity method investment gain		(1,333,000)	0
Stock options		670,000	1,561,000
Other, net		(263,000)	(1,000)
Total		78,813,000	57,329,000
Valuation allowance		(78,813,000)	(61,844,000)
Net deferred tax liabilities		$ 0	$ (4,515,000)
Income tax rate reconciliation [Abstract]
Computed tax benefit at federal statutory rate		34.00%	34.00%	34.00%
Research & development and other credits		2.00%	3.00%	0.00%
Permanent differences		(4.00%)	(1.00%)	(15.00%)
Losses for which no benefit has been recognized		(34.00%)	(24.00%)	(18.00%)
State tax benefit, net of effect on federal income taxes		10.00%	3.00%	4.00%
Foreign rate differential		(1.00%)	(1.00%)	1.00%
Total		7.00%	14.00%	6.00%
Net operating loss carryforwards for federal tax purposes		$ 168,800,000
Net operating loss carryforwards for state tax purposes		105,300,000
Tax Credit Carryforward [Line Items]
Deferred income tax benefit		(4,516,000)	$ (7,376,000)	$ (3,281,000)
Deferred federal income tax benefit		(4,800,000)	(5,200,000)
Deferred state income tax benefit		$ 290,000	$ (2,200,000)
Percentage of change in ownership		50.00%
Period in which change of ownership for a specified percentage should occur		3 years
BioTime Subsidiaries [Member]
Tax Credit Carryforward [Line Items]
Foreign net operating loss carryforwards		$ 59,700,000
Amount utilized in net operating loss carryforwards		$ 9,100,000
Asterias Biotherapeutics [Member]
Tax Credit Carryforward [Line Items]
Number of shares sold by subsidiary (in shares)	5,000,000
Taxable gain on sale of subsidiary shares	$ 10,300,000
OncoCyte Corporation [Member]
Tax Credit Carryforward [Line Items]
Number of shares sold by subsidiary (in shares)		259,712	406,756
Taxable gain on sale of subsidiary shares		$ 815,000	$ 1,300,000
Shares distributed to shareholders (in shares)		4,700,000
Taxable gain on shares distribution		$ 7,400,000
Shares received in noncash transactions (in shares)		192,644
Gains on sale of investments		$ 819,000
Federal [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards		4,100,000
State [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards		$ 4,200,000

Enterprise-wide Disclosures (Details)

12 Months Ended

Dec. 31, 2015

USD ($)

Customer

Grant

Dec. 31, 2014

USD ($)

Grant

Dec. 31, 2013

USD ($)

Sep. 30, 2011

USD ($)

Revenues from External Customers and Long-Lived Assets [Line Items]

Total revenues

$ 7,036,000

$ 5,244,000

$ 4,434,000

Revenue, Major Customer [Line Items]

Number of major customers | Customer

Number of major grants | Grant

Award granted from research project

$ 3,800,000

2,600,000

Grants revenue

4,502,000

3,297,000

1,573,000

Domestic [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Total revenues

5,976,000

3,586,000

2,106,000

Asia [Member]

Revenues from External Customers and Long-Lived Assets [Line Items]

Total revenues

$ 1,060,000

$ 1,658,000

$ 2,328,000

Hospira [Member]

Revenue, Major Customer [Line Items]

Percentage of total revenues

2.00%

3.00%

6.50%

CJ Health [Member]

Revenue, Major Customer [Line Items]

Percentage of total revenues

0.30%

1.00%

1.70%

GE Health [Member]

Revenue, Major Customer [Line Items]

Percentage of total revenues

4.80%

0.00%

Summit [Member]

Revenue, Major Customer [Line Items]

Percentage of total revenues

^[1]

0.00%

20.30%

CIRM [Member]

Revenue, Major Customer [Line Items]

Grant Award

$ 14,300,000

Percentage of total revenues

42.70%

19.70%

0.00%

N I H [Member]

Revenue, Major Customer [Line Items]

Number of major grants | Grant

Percentage of total revenues

6.50%

12.50%

5.00%

N I H [Member] | 2011 NIH Grant [Member]

Revenue, Major Customer [Line Items]

Award granted from research project

$ 336,000

Payment received from research project

$ 117,000

Grants revenue

110,000

N I H [Member] | 2013 NIH Contract [Member]

Revenue, Major Customer [Line Items]

Award granted from research project

$ 285,000

Payment received from research project

$ 214,000

214,000

Grants revenue

110,000

N I H [Member] | 2014 NIH Grant #1 [Member]

Revenue, Major Customer [Line Items]

Award granted from research project

270,262

Payment received from research project

199,000

72,000

Grants revenue

143,000

128,000

N I H [Member] | 2014 NIH Grant #2 [Member]

Revenue, Major Customer [Line Items]

Award granted from research project

292,262

Payment received from research project

227,000

65,000

Grants revenue

175,000

117,000

N I H [Member] | 2014 NIH Grant #3 [Member]

Revenue, Major Customer [Line Items]

Award granted from research project

224,911

Payment received from research project

161,000

64,000

Grants revenue

$ 138,000

$ 87,000

OCS [Member]

Revenue, Major Customer [Line Items]

Percentage of total revenues

14.40%

31.30%

27.90%

Subscription and Advertising (various customers) [Member]

Revenue, Major Customer [Line Items]

Percentage of total revenues

29.40%

32.50%

38.60%

Cell Cure Neurosciences, Ltd. [Member]

Revenue, Major Customer [Line Items]

Grants revenue

$ 1,000,000

$ 1,600,000

LifeMap Sciences, Ltd. [Member]

Revenue, Major Customer [Line Items]

Payment received from research project

1,357,000

1,000,000

Advertising revenue

679,000

621,000

Revenues of royalty and commission fees

678,000

552,000

Asterias [Member]

Revenue, Major Customer [Line Items]

Grants revenue

$ 2,700,000

$ 1,000,000

[1]	BioTime recognized the unamortized balance of the Summit license fees during the fourth quarter of 2013 as a result of the termination of its license agreements with Summit.

Selected Quarterly Financial Information (UNAUDITED) (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Selected Quarterly Financial Information [Abstract]

Revenues, net

$ 1,311

$ 1,874

$ 1,749

$ 1,000

$ 1,665

$ 960

$ 855

$ 935

$ 7,036

$ 5,244

$ 4,434

Operating expenses

23,009

18,978

15,245

14,502

16,069

13,098

13,917

12,073

71,738

55,089

59,627

Loss from operations

(21,698)

(17,104)

(13,496)

(13,502)

(14,405)

(12,138)

(13,062)

(11,138)

(65,809)

(50,682)

(55,986)

Net loss attributable to BioTime, Inc.

$ (14,747)

^[1]

$ (13,626)

^[1]

$ (2,305)

^[1]

$ (10,167)

^[1]

$ (10,568)

^[1]

$ (8,268)

^[1]

$ (9,520)

^[1]

$ (8,099)

^[1]

$ (46,991)

$ (36,412)

$ (43,883)

Basic and diluted net loss per share (in dollars per share)

$ (0.16)

$ (0.18)

$ (0.12)

$ (0.13)

$ (0.14)

$ (0.12)

$ (0.16)

$ (0.14)

$ (0.59)

$ (0.55)

$ (0.81)

Deferred income tax benefit

$ (4,516)

$ (7,376)

$ (3,281)

[1]	Net of $4.5 million and $7.4 million of deferred income tax benefits for 2015 and 2014 respectively.

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Subsequent Events (Details)		1 Months Ended
Subsequent Events (Details)	Feb. 29, 2016 USD ($) $ / shares shares	Jan. 31, 2016 Extension $ / shares shares	Dec. 31, 2015 $ / shares	Dec. 31, 2014 $ / shares	Dec. 31, 2013 shares
Subsequent Event [Line Items]
Common stock, par value (in dollars per share) \| $ / shares			$ 0	$ 0
Number of warrant shares purchases through exercise of each warrant (in shares)					8,000,000
Subsequent Event [Member] \| OncoCyte [member]
Subsequent Event [Line Items]
Common stock purchased upon exercise of warrants (in shares)		4,744,707
Common stock, par value (in dollars per share) \| $ / shares		$ 0
Number of warrant shares purchases through exercise of each warrant (in shares)		1.1
Warrant share purchase price (in dollars per share) \| $ / shares		$ 4.55
Maximum percentage of royalty amount subject to reduction in net sales		50.00%
Maximum number of one year extensions available to purchase \| Extension		3
Subsequent Event [Member] \| OncoCyte [member] \| Minimum [Member]
Subsequent Event [Line Items]
Royalty payment percentage range		3.00%
Subsequent Event [Member] \| OncoCyte [member] \| Maximum [Member]
Subsequent Event [Line Items]
Royalty payment percentage range		5.00%
Subsequent Event [Member] \| Asterias Biotherapeutics, Inc. [Member]
Subsequent Event [Line Items]
Annual base salary \| $	$ 452,400
Number of stock options granted to executive (in shares)	1,000,000
Stock options exercise price \| $ / shares	$ 3.64
Stock options vest in equal monthly installments vesting period	48 months
Period consider for severance benefits in one year or less than service	6 months
Percentage of annual base salary eligible for bonus in one year or less than service	50.00%
Period consider for severance benefits in more than one year service	12 months
Percentage of annual base salary eligible for bonus in more than one year service	100.00%
Percentage of annual base salary eligible for bonus in case of termination without cause	100.00%
Percentage of annual base salary eligible in case of termination without cause	100.00%
Subsequent Event [Member] \| Asterias Biotherapeutics, Inc. [Member] \| Restricted Stock [Member]
Subsequent Event [Line Items]
Number of restricted shares granted to executive (in shares)	200,000
Stock options vesting percentage	50.00%
Subsequent Event [Member] \| Asterias Biotherapeutics, Inc. [Member] \| Stock Option [Member]
Subsequent Event [Line Items]
Stock options vesting percentage	50.00%
Subsequent Event [Member] \| Asterias Biotherapeutics, Inc. [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Percentage of annual base salary eligible for bonus	50.00%

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)	Dec. 31, 2013 shares
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY [Abstract]
Warrants issued as part of investment in subsidiary (in shares)	8,000,000

Segment Information (Details)	12 Months Ended
Segment Information (Details)	Dec. 31, 2015 Segment
Segment Information [Abstract]
Number of operating segments	1